A Practical Guide to Newborn Bloodspot Screening In Ireland

9th Edition May 2022

National Newborn Bloodspot Screening Laboratory
Children’s Health Ireland at Temple Street
Temple Street, Dublin D01 YC67

9th Edition – May 2022
Next review due May 2024
Contents
INTRODUCTION ........................................................................................................................................... 6
Significant changes from 8th Edition .......................................................................................................... 7
1 Contact Details and Laboratory Opening Times .................................................................................. 8
  1.1 Telephone Numbers ....................................................................................................................... 8
  1.2 Laboratory Opening Times ............................................................................................................. 8
2 Abbreviations ......................................................................................................................................... 9
3 Conditions Screened ............................................................................................................................. 10
  3.1 Mode of Inheritance ...................................................................................................................... 11
  3.2 Conditions included in the Irish Screening Programme ................................................................. 12
    3.2.1 Phenylketonuria (PKU) ............................................................................................................. 12
    3.2.2 Maple Syrup Urine Disease (MSUD) ........................................................................................ 12
    3.2.3 Homocystinuria (HCU) ............................................................................................................ 13
    3.2.4 Classical Galactosaemia (CGAL) ................................................................................................ 14
    3.2.5 Cystic Fibrosis (CF) .................................................................................................................... 15
    3.2.6 Congenital Hypothyroidism (CHT) ............................................................................................. 17
    3.2.7 Medium Chain Acyl CoA Dehydrogenase deficiency (MCADD) .............................................. 18
    3.2.8 Glutaric Aciduria Type 1 (GA1) ................................................................................................ 19
    3.2.9 Adenosine Deaminase deficient Severe Combined Immunodeficiency (ADA-SCID) .............. 20
4 Responsibility for ensuring all babies are offered newborn bloodspot screening ................... 21
  4.1 Responsibility of the Health Service Executive ............................................................................. 23
  4.2 Responsibility and role of the NNBSP Governance Group ......................................................... 23
  4.3 Responsibility of Community Healthcare Organisation (CHO) Child health leads ........... 23
  4.4 Responsibility of Maternity Units and Maternity Hospitals ....................................................... 23
  4.5 Responsibility of the public health nursing service in the CHO ................................................. 24
  4.6 Responsibility of GP’s, self-employed community and private midwives .................................. 24
  4.7 Responsibility of parents/legal guardians ..................................................................................... 24
  4.8 Responsibility of the national newborn bloodspot screening laboratory (NNBSL) ............. 25
5 Consent for Newborn Screening .......................................................................................................... 25
  5.1 General overview ........................................................................................................................... 25
  5.2 Consent and responsibility for obtaining consent ..................................................................... 25
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.3</td>
<td>Who can give consent</td>
<td>26</td>
</tr>
<tr>
<td>5.4</td>
<td>Other circumstances</td>
<td>28</td>
</tr>
<tr>
<td>5.5</td>
<td>Literacy difficulties</td>
<td>29</td>
</tr>
<tr>
<td>5.6</td>
<td>Right to opt-out of newborn screening</td>
<td>29</td>
</tr>
<tr>
<td>5.7</td>
<td>Informing parent(s)/legal guardian(s) about the programme</td>
<td>30</td>
</tr>
<tr>
<td>5.8</td>
<td>Retention of the Newborn Bloodspot Screening Card</td>
<td>31</td>
</tr>
<tr>
<td>5.9</td>
<td>Data protection legislation, GDPR and newborn bloodspot screening</td>
<td>31</td>
</tr>
<tr>
<td>5.10</td>
<td>Return or disposal of newborn bloodspot screening cards</td>
<td>32</td>
</tr>
<tr>
<td>6</td>
<td>Sample Collection</td>
<td>33</td>
</tr>
<tr>
<td>6.1</td>
<td>Feeds at time of sample collection</td>
<td>33</td>
</tr>
<tr>
<td>6.1.1</td>
<td>Breast or formula fed babies</td>
<td>33</td>
</tr>
<tr>
<td>6.1.2</td>
<td>Babies on total parenteral nutrition, intravenous fluids and soya feeds</td>
<td>34</td>
</tr>
<tr>
<td>6.1.3</td>
<td>Feeds protocol for high risk (sibling) MCADD screens</td>
<td>34</td>
</tr>
<tr>
<td>6.2</td>
<td>Babies receiving red blood cell (RBC) transfusions</td>
<td>35</td>
</tr>
<tr>
<td>6.3</td>
<td>Preterm and low birth weight babies</td>
<td>35</td>
</tr>
<tr>
<td>6.4</td>
<td>High Risk Screening for Metabolic Disorders</td>
<td>35</td>
</tr>
<tr>
<td>6.4.1</td>
<td>Family history of a metabolic disorder in extended family</td>
<td>38</td>
</tr>
<tr>
<td>6.4.2</td>
<td>Consanguinity and Endogamous populations</td>
<td>38</td>
</tr>
<tr>
<td>6.4.3</td>
<td>Maternal phenylketonuria (PKU)</td>
<td>38</td>
</tr>
<tr>
<td>6.5</td>
<td>High Risk Screening for Other Disorders</td>
<td>38</td>
</tr>
<tr>
<td>6.6</td>
<td>Babies born to immigrant parents or refugees</td>
<td>39</td>
</tr>
<tr>
<td>6.6.1</td>
<td>Arriving before NBS has been performed in country of birth</td>
<td>39</td>
</tr>
<tr>
<td>6.6.2</td>
<td>Arriving after NBS screen has been performed in country of birth</td>
<td>39</td>
</tr>
<tr>
<td>6.7</td>
<td>Babies presenting with meconium ileus at birth</td>
<td>40</td>
</tr>
<tr>
<td>6.8</td>
<td>Infants over six weeks who missed CF screening due to programme issue</td>
<td>40</td>
</tr>
<tr>
<td>7</td>
<td>Recording of Information</td>
<td>42</td>
</tr>
<tr>
<td>7.1</td>
<td>UPI, hospital codes and correct recording of LHOs</td>
<td>42</td>
</tr>
<tr>
<td>7.2</td>
<td>Recording of results of newborn blood spot screen</td>
<td>44</td>
</tr>
<tr>
<td>7.3</td>
<td>Discharges from hospital before NBS</td>
<td>44</td>
</tr>
<tr>
<td>7.3.1</td>
<td>Newborn bloodspot screening to be performed by PHN</td>
<td>45</td>
</tr>
<tr>
<td>7.3.2</td>
<td>Newborn screening performed by GP or independent midwife</td>
<td>45</td>
</tr>
<tr>
<td>7.4</td>
<td>Transfer from maternity unit/hospital to another hospital</td>
<td>46</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Procedure for taking the routine blood sample</td>
<td></td>
</tr>
<tr>
<td>8.1</td>
<td>Completion of the newborn bloodspot screening card</td>
<td></td>
</tr>
<tr>
<td>8.2</td>
<td>Equipment required</td>
<td></td>
</tr>
<tr>
<td>8.3</td>
<td>Technique for Sample Collection</td>
<td></td>
</tr>
<tr>
<td>8.4</td>
<td>Sample collection from central line in sick babies</td>
<td></td>
</tr>
<tr>
<td>8.5</td>
<td>Packing and dispatching the newborn bloodspot screening cards</td>
<td></td>
</tr>
<tr>
<td>8.6</td>
<td>Quality of the bloodspot sample</td>
<td></td>
</tr>
<tr>
<td>8.7</td>
<td>Why repeat blood samples may be requested</td>
<td></td>
</tr>
<tr>
<td>8.8</td>
<td>Problems with card demographics incorrectly completed</td>
<td></td>
</tr>
<tr>
<td>8.9</td>
<td>Bio-hazard samples</td>
<td></td>
</tr>
<tr>
<td>8.10</td>
<td>Completion of newborn bloodspot screening card at time of discharge</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Transport / drying boxes and pre-printed plastic envelopes</td>
<td></td>
</tr>
<tr>
<td>9.1</td>
<td>Procedure for transporting samples</td>
<td></td>
</tr>
<tr>
<td>9.2</td>
<td>Responsibility of sender</td>
<td></td>
</tr>
<tr>
<td>9.3</td>
<td>Red weather alerts</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Procedure for reporting results</td>
<td></td>
</tr>
<tr>
<td>10.1</td>
<td>Setting up authorised users for eReports</td>
<td></td>
</tr>
<tr>
<td>10.2</td>
<td>Requests for repeat sampling and responsibility for checking eReports</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Procedure for contacting parent(s)/legal guardian(s) with a screen positive result</td>
<td></td>
</tr>
<tr>
<td>11.1</td>
<td>Follow up for suspected positive cases of PKU</td>
<td></td>
</tr>
<tr>
<td>11.2</td>
<td>Follow up for suspected positive cases of MSUD</td>
<td></td>
</tr>
<tr>
<td>11.3</td>
<td>Follow up for suspected positive cases of HCU</td>
<td></td>
</tr>
<tr>
<td>11.4</td>
<td>Follow up for suspected positive cases of Classical Galactosaemia</td>
<td></td>
</tr>
<tr>
<td>11.5</td>
<td>Follow up for suspected positive cases of MCADD</td>
<td></td>
</tr>
<tr>
<td>11.6</td>
<td>Follow up for suspected positive cases of GA1</td>
<td></td>
</tr>
<tr>
<td>11.7</td>
<td>Follow up for suspected positive cases of Cystic Fibrosis</td>
<td></td>
</tr>
<tr>
<td>11.8</td>
<td>Follow up for suspected positive cases of Congenital Hypothyroidism</td>
<td></td>
</tr>
<tr>
<td>11.9</td>
<td>Follow up for suspected positive cases of ADA-SCID</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Appendices</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appendix No. 1 Incorrect Location Form</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appendix No. 2 Opt Out Form</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appendix No. 3 Scan of Newborn Screening card (front and back)</td>
<td></td>
</tr>
<tr>
<td>Appendix No.</td>
<td>Description</td>
<td>Page</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Appendix No. 4</td>
<td>Copy result request form</td>
<td>67</td>
</tr>
<tr>
<td>Appendix No. 5</td>
<td>Specimen Gate eReports™ instructions</td>
<td>68</td>
</tr>
<tr>
<td>Appendix No. 6</td>
<td>Patient Detail Amendment form</td>
<td>70</td>
</tr>
<tr>
<td>Appendix No. 7</td>
<td>Metabolic follow-up sample request form</td>
<td>71</td>
</tr>
<tr>
<td>Appendix No. 8</td>
<td>ADA SCID follow up sample request form</td>
<td>72</td>
</tr>
<tr>
<td>Appendix No. 9</td>
<td>Sample Checklist</td>
<td>73</td>
</tr>
</tbody>
</table>
INTRODUCTION

The Newborn Screening Programme for phenylketonuria (PKU) was started in Ireland on behalf of the Department of Health by Drs Seamus Cahalane and Doreen Murphy at the Children’s University Hospital, Temple Street in February 1966; approximately four years after the first newborns were screened in the States of Massachusetts and New York (USA). The Irish programme was one of the first programmes in the world. Other conditions have since been added. Some of these have been discontinued and others will be added in the future. In December 2018 two additional metabolic disorders; MCADD and GA1 were added to the screening programme. May 2022 marked the introduction of screening for an immunological disorder, ADA-SCID.

The screening programme involves many healthcare professionals, each with their own expertise and responsibilities. The programme is co-ordinated through the National Newborn Bloodspot Screening Laboratory (NNBSL) at CHI Temple Street, on behalf of the Health Service Executive (HSE) and the Directorate of Health and Wellbeing – Public Health and Child Health. The screening laboratory is fully integrated into the Hospital’s Department of Paediatric and Laboratory Medicine in Temple St., thus ensuring rapid confirmatory testing of abnormal screens and the biochemical monitoring of those diagnosed.

The worldwide screening community is small and we in Ireland are very cognisant of the differences between regional and national programmes and the Irish programme. The Irish programme has been tailored for the local population and the incidence of disorders occurring within the Irish population. The National Newborn Bloodspot Screening Programme (NNBSP) will continue to develop as new information and treatments become available for these rare disorders.

We would like to acknowledge the dedication and commitment that so many different healthcare professionals put into this programme for the benefit of the few babies born each year who are affected by one of these conditions.

We welcome any comments and feedback that individuals may have on this edition. More information about the programme may be obtained at www.newbornscreening.ie and www.hse.ie/go/newbornscreening
Significant changes from 8th Edition

Some of the more significant changes which have been incorporated into this edition are highlighted below. However, users are advised to read the entire guide in order to familiarise themselves fully.

Section 3: Summary information on the additional disorder introduced to the programme: Adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID). This is a form of severe combined immunodeficiency (SCID) which causes a deficiency of the enzyme adenosine deaminase (ADA). If not detected and treated early ADA-SCID can be life-threatening. Haematopoietic stem cell transplantation (HSCT) is the definitive treatment and results in good overall outcome for the patient, gene therapy is an option for those without a matched donor.

Section 5: Update on consent protocol to reflect updated HSE National Consent Policy
Section 6: Clarification on sub-optimal feeding issues
Section 6: ADA-SCID high risk screening guidelines

Important Messages:

Parent(s)/legal guardian(s) are entitled to and can be given a copy of their baby’s results by their PHN.

N.B.: No screening test is 100% reliable
The purpose of newborn screening is to identify infants at risk that require more definitive testing. As with all screening programmes both false negatives and false positives are possible.

Important information for samples due to be taken on Thursdays (all year round)
To ensure samples reach the laboratory in a timely manner and to minimise a delay in reporting, can we ask that samples due to be taken on a Thursday, are collected early Thursday morning if **baby is 72 hours old**, allow sample to dry fully, and **post on Thursday afternoon** to arrive in our laboratory on Friday morning for analysis.
1 Contact Details and Laboratory Opening Times

1.1 Telephone Numbers

National Newborn Bloodspot Screening Laboratory (NNBSL)
Enquiries: 01 878 4277, 878 4610
Email: info.newbornscreening@cuh.ie

Fax: 01 878 4596
Website: www.newbornscreening.ie

National Centre for Inherited Metabolic Disorders (NCIMD)
Temple St., Enquiries to 01 878 4317

1.2 Laboratory Opening Times

Monday to Friday 09.00 to 17.00
Analysis including Beutler tests and reporting of results

All samples received in the laboratory up to 12.00 on routine days will be analysed that day, samples received after that will be analysed the next working day. The 12.00 deadline may change on Christmas Eve/ New Year, sample takers will be notified in advance. Samples received after deadline and on a Friday or received over the weekend are processed on the first run on the next working day.

Saturday Morning 09.00 to 12.00
Reporting of results and Beutler Assay
N.B. Beutler samples must be in the laboratory before 10.00am on Saturdays and Bank holiday Monday, the test takes approx 2.5hrs and all maternity units are phoned with results. Samples will not be reported electronically until the next working day.
To facilitate phoning of results please note contact number where Beutler results are to be phoned back to.

Christmas/ New Year: Changes of opening hours will be circulated in advance.
2 Abbreviations

ADA-SCID  Adenosine deaminase-deficient severe combined immunodeficiency
ADOM/PHN  Assistant Director of Midwifery/Public Health Nursing
CHO  Community Healthcare Organisation
CHI  Children’s Health Ireland
CHT  Congenital Hypothyroidism
CF  Cystic Fibrosis
CFTR  Cystic Fibrosis Transmembrane Conductance Regulator
C Gal  Classical Galactosaemia
CLN  Clinical liaison nurse
DBS  Dried blood spot
DPHN  Department of Public Health Nursing
DOB  Date of Birth
DON/M  Director of Nursing/Midwifery
GA1  Glutaric Aciduria type 1
GCDH  Glutaryl-CoA dehydrogenase
GDPR  General Data Protection Regulation
GP  General Practitioner
HCRN  Health Care Record Number
HCU  Homocystinuria
HIPE  Hospital Inpatient Enquiry
HSE  Health Service Executive
IHI  Individual Health Identifier
IV  Intravenous (fluids)
KPI  Key Performance Indicators
IRT  Immunoreactive Trypsinogen
LHO  Local Health Office
MCADD  Medium chain Acyl CoA dehydrogenase deficiency
MSUD  Maple Syrup Urine Disease
NBS  Newborn Bloodspot Screening
NBSC  Newborn Bloodspot Screening Card
NCIMD  National Centre for Inherited Metabolic Disorders
NNBSL  National Newborn Bloodspot Screening Laboratory
NNBSP  National Newborn Bloodspot Screening Programme
NSAC  National Screening Advisory Committee
OLCHC  Our Lady’s Children’s Hospital, Crumlin
PHN  Public Health Nurse
PKU  Phenylketonuria
RBC  Red Blood Cell
SCBU  Special Care Baby Unit
SECM  Self-employed community midwives
TPN  Total Parenteral Nutrition
TS  Temple Street
TSH  Thyroid Stimulating Hormone
UPI  Unique parenteral identifier
3 Conditions Screened

All conditions which form part of the Newborn Bloodspot Screening Programme, have been selected because they all have a relatively high incidence within the Irish population and they fulfil, in part or in full, the criteria which have been set out internationally for newborn screening. These include:

- the conditions screened are treatable;
- there is a test available which is easily applied to large population groups;
- there are few false positive and false negative results i.e. the test is reliable;
- the incidence of the conditions in the community is sufficiently high to warrant screening;
- the cost of screening makes the process cost-effective.

For all of the conditions, early diagnosis and treatment significantly improves the clinical outcome. Some of the conditions, for example Phenylketonuria, Congenital Hypothyroidism, Classical Galactosaemia, Maple Syrup Urine Disease, Medium Chain Acyl CoA Dehydrogenase deficiency, Glutaric Aciduria Type 1 and ADA-SCID benefit from the earliest detection possible. Unfortunately, as with all screening programmes, not all individuals with a condition will be detected. This is particularly true for Homocystinuria and for Cystic Fibrosis where milder variants of the condition may not be detected.

N.B.: No screening test is 100% reliable

Table 1: Conditions included in the Irish Newborn Bloodspot Screening Programme

<table>
<thead>
<tr>
<th>Condition</th>
<th>Date started</th>
<th>Irish Incidence</th>
<th>Worldwide Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Phenylketonuria (PKU)</td>
<td>1966</td>
<td>1:4,500</td>
<td>1:12,000</td>
</tr>
<tr>
<td>2. Homocystinuria (HCU)</td>
<td>1971</td>
<td>1:69,400</td>
<td>1:120,000</td>
</tr>
<tr>
<td>3. Classical Galactosaemia (CGal)</td>
<td>1972</td>
<td>1:16,200</td>
<td>1:45,000</td>
</tr>
<tr>
<td>4. Maple Syrup Urine Disease (MSUD)</td>
<td>1972</td>
<td>1:155,200</td>
<td>1:225,000</td>
</tr>
<tr>
<td>5. Congenital Hypothyroidism (CHT)</td>
<td>1979</td>
<td>1:2,300</td>
<td>1:3,500</td>
</tr>
<tr>
<td>6. Cystic Fibrosis (CF)</td>
<td>2011</td>
<td>1:2,300</td>
<td>1:3,500</td>
</tr>
<tr>
<td>7. Glutaric Aciduria Type 1 (GA1)</td>
<td>2018</td>
<td>1:54,000</td>
<td>1:100,000</td>
</tr>
<tr>
<td>8. Medium Chain Acyl CoA Dehydrogenase deficiency (MCADD)</td>
<td>2018</td>
<td>1:66,000</td>
<td>1:14,600</td>
</tr>
<tr>
<td>9. Adenosine Deaminase-Deficient Severe Combined Immunodeficiency</td>
<td>2022</td>
<td>1:78,500</td>
<td>1:200,000*</td>
</tr>
</tbody>
</table>

*https://www.orpha.net/consor/cgibin/OC_Exp.php?Lng=GB&Expert=277#:~:text=SCID%20due%20to%20ADA%20deficiency.males%20and%20females%20are%20affected.
3.1 Mode of Inheritance

The majority of the conditions screened for involve a defect in a metabolic process or pathway and are inherited as ‘autosomal’ conditions and can occur with equal frequency in both males and females.

Each step in a metabolic pathway is governed by an enzyme. An enzyme is a protein produced by a set (two) of genes on a pair of chromosomes. Each parent transfers to their off-spring one gene so that the off-spring has a set assembled from both parents. If one of these genes is defective (mutated), the metabolic pathway continues but at a reduced rate. These individuals, known as carriers, do not have symptoms of the condition but carry the defective gene. For autosomal recessively inherited conditions, both parents must be carriers of a defective gene and each of their off-spring has a one in four chance of having the condition and a one in two chance of being a carrier.

The clinical presentation and severity of the condition may vary between unrelated families. Different mutations may affect the same metabolic process differently; some individuals may present with a severe form of the condition and others with a very mild form.

Congenital hypothyroidism is slightly different in that for 90% of cases the condition just occurs, for reasons which are not fully understood; it is twice as common in girls as in boys. However, for one in 10 babies (10%) the condition is inherited as an autosomal recessive condition, as described above.
3.2 Conditions included in the Irish Screening Programme

3.2.1 Phenylketonuria (PKU)

**Screening case definition:** to detect babies with Phenylketonuria (PKU). No distinction is made between those with PKU, hyperphenylalaninaemia and Dihydropteridine Reductase deficiency. Although it must be acknowledged that some babies with mild hyperphenylalaninaemia may not be detected by newborn screening as the blood level of the amino acid phenylalanine may be below the action cut-off level when screened.

Phenylketonuria is an autosomal recessive condition involving the breakdown of the amino acid phenylalanine. Approximately one in every 4,500 babies born in Ireland has PKU or a milder form called hyperphenylalaninaemia. When diagnosed within the newborn period and started on treatment, these babies grow up healthy and well. However, without treatment this condition may cause intellectual or physical disability.

In the majority of cases, the condition is caused by a lack of the enzyme phenylalanine hydroxylase, which normally converts phenylalanine, one of the building blocks in protein, into tyrosine. In the absence of the enzyme, phenylalanine accumulates and these high levels have a direct toxic effect on the brain.

Early treatment is very beneficial; it aims at giving a reduced intake of phenylalanine but a normal intake of all the other amino acids. This diet has to be continued for life. The screening test depends on detecting a high level of phenylalanine in the blood. If the test is carried out before 72 hours after birth, there is a possibility that the level of phenylalanine in blood may not be sufficiently elevated for the condition to be detected.

The treatment for PKU has been one of the major successes in medicine since it was first introduced in the early 1950s. There is substantial evidence to show that the earlier the treatment is started, the better the biochemical control throughout life and the better the outcome.

3.2.2 Maple Syrup Urine Disease (MSUD)

**Screening case definition:** to detect babies with the more severe neonatal onset form of Maple Syrup Urine Disease (MSUD). The programme may not detect those babies with the milder variants such as late onset or intermittent MSUD.

Maple Syrup Urine Disease is a life threatening condition if it is not detected and treated early. It too is an autosomal recessive condition caused by a defect in the metabolism of three amino acids, known as the branched chain amino acids because of their similar biochemical structure. Approximately one in every 155, 200 babies born in Ireland may have this condition or about one baby born every two to three years. The disorder is so called because the urine may have an odour similar to that of maple syrup.

Screening was originally justified on the basis that chronic handicap and even premature death had occurred in a number of families where this condition had gone undetected.
The branched chain amino acids accumulate in blood following the establishment of feeding during the first few days of life, and may cause brain damage.

A diet similar to that for PKU but with low levels of the branched-chain amino acids is started as soon as the diagnosis is made. Normal brain development and good health result from early treatment; life-long adherence to the diet is essential. Urgent medical intervention may be required during illness, which may be precipitated by infection or stress.

3.2.3 Homocystinuria (HCU)

**Screening case definition:** to detect babies with Classical Homocystinuria (HCU).

The programme may not detect those babies with the milder variants such as those with pyridoxine (vitamin B₆) responsive HCU and babies with inadequate protein intake.

Homocystinuria results from the accumulation in blood of the amino acid methionine and one of its metabolic products homocysteine. Homocysteine accumulates due to a deficiency of the enzyme cystathionine β-synthase. Homocysteine is toxic to the lining of blood vessels and predisposes the individual to thrombus formation, blood clots and a number of other complications including osteoporosis (thinning of the bones) and dislocation of the lens of the eye. Again the treatment is similar to that for PKU. For those individuals who adhere to the diet, the risk of developing any of the complications is greatly reduced. Approximately one in every 69,400 babies born in Ireland may have the condition or one baby every year.

The screening programme detects high blood levels of methionine. This is one of the more difficult conditions to detect, as the blood methionine level may not be raised initially. The methionine concentration is low in many baby foods, particularly in breast milk. The screening programme may not detect approximately one in every five babies born with this condition. There are a variety of reasons why this may occur. These include:

- Breast fed babies as there may be an inadequate intake of methionine in the feed to enable the blood methionine level to rise above the level for diagnosis.
- A milder vitamin B₆ responsive form of the condition. These patients usually have milder symptoms and disease progression is slower and they are unlikely to be detected by newborn screening.

Consequently, if protein intake is deemed to be suboptimal, a further sample should be taken on or about day 10 of life for Homocystinuria screening. All babies or children who present clinically in later life with signs and symptoms suggestive of Homocystinuria, such as dislocation of lenses, osteoporosis or inappropriate tall stature should have the disorder excluded formally by measuring plasma levels of methionine and total homocysteine.
3.2.4 Classical Galactosaemia (CGAL)

**Screening case definition:** to detect babies with Classical Galactosaemia.

The programme tries to avoid diagnosing individuals with non-classical galactosaemia such as the Duarte/Galactosaemia variant as they usually remain asymptomatic throughout life. The NNBSP does not screen for Epimerase or Galactose Kinase deficiency.

Classical Galactosaemia is an autosomal recessive condition caused by the deficiency of the enzyme galactose-1-phosphate uridyl transferase. This enzyme is important for the breakdown of galactose, one of the two sugars that make up lactose in human and cow’s milk. Approximately 1 in every 16,200 babies born in Ireland each year may have this condition. However, it is particularly common among babies born to Irish Traveller parents in whom the incidence is approximately 1 in 450 births. Consequently, in the non-traveller Irish community the incidence is about one in every 36,000 births.

If not detected and treated during infancy, the disorder may cause damage to the liver or there may be an increased risk of infection, which may be life threatening. As a result of the condition, galactose and its metabolite galactose-1-phosphate accumulate in blood. Galactose-1-phosphate is extremely toxic. The baby may present with jaundice and there may be a bleeding disorder with a tendency to bleed spontaneously. The affected baby may also develop an *E. coli* infection of the blood, septicaemia or present with cataracts in their eyes. Early detection and treatment with a lactose or galactose-free diet will prevent the early clinical complications of the disorder; some of the longer term complications, such as dyspraxia, ataxia or reduced fertility in women, may still occur in older children and adults despite dietary treatment.

Because the condition is more common in babies born to Irish Traveller parents and to siblings of known cases, a special screening test, the Beutler test, is offered to all these babies at birth (preferably Day 1 of life). Parents/legal guardians are advised to keep baby on a galactose free feed (Soya-based) until the result of the Beutler test is available. This protects the baby should he/she have the condition. For those mothers wishing to breast feed, they should discuss this with their midwife as they can express their milk until the result of the Beutler test is available.

Clinicians should never depend upon the general population screening for the diagnosis of Classical Galactosaemia, but should query this condition in any baby who presents early with jaundice and other symptoms suggestive of Galactosaemia e.g. vomiting, floppiness, hypoglycaemia, conjugated hyperbilirubinaemia or abnormal clotting of unknown cause.
3.2.5 Cystic Fibrosis (CF)

Screening case definition: to detect babies with Cystic Fibrosis (CF) who would have presented clinically with significant respiratory symptoms or fat malabsorption. The programme is not designed to detect individuals with minor respiratory symptoms or other symptoms, such as infertility in men due to congenital absence of the vas deferens.

Ireland has one of the highest incidences of CF in the World with approximately one in every 2,300 babies being affected. CF is also an autosomal recessive condition with both parents carrying an abnormal Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.

As a consequence of the condition, thick mucus secretions are produced by a number of organs including the lungs and pancreas; it is this thick mucus secretion which causes the problems. The thick secretions in the lungs may become infected, ultimately causing damage to the lungs. If the pancreas is involved this may cause diabetes mellitus, digestive problems and malabsorption of important vitamins. Consequently babies with CF may present with failure to thrive and frequent chest infections.

Newborn blood spot screening means that babies with CF are identified earlier; they can be treated with a high energy diet to improve weight gain and medicines and physiotherapy to improve lung function. Although a child with CF may still become ill, early treatment does improve their quality of life, significantly reducing length of stay in hospital. They can live healthier and longer lives. Specific treatment is now available for a significant number of persons with CF depending on the specific mutation affecting the CFTR gene.

The screening programme measures the blood level of immunoreactive trypsinogen (IRT). IRT is normally excreted by the pancreas into the intestinal tract, but in individuals with CF, it is regurgitated back into the blood due to the thick mucus secretions which block the pancreatic ducts. Levels of IRT may remain high in blood for about the first six weeks of life. If the blood IRT level is high the sample will be referred for CFTR mutational analysis. This DNA test screens for the presence of 38 possible mutations on the original bloodspot collected.

- If two CF mutations on the newborn screening sample are identified, then the baby probably has CF and this will be confirmed by a sweat test which will be organised and carried out by the baby’s local CF centre without delay.
- If one mutation is identified then a sweat test will be performed to determine whether the baby is a carrier of CF or has the condition. If the sweat test is positive, further DNA analysis will be undertaken to identify the second mutation.
Figure 1: Algorithm for Newborn Screening for Cystic Fibrosis

The ‘sweat test’ used to confirm or out-rule CF, measures the chloride concentration in sweat, and is usually performed before the fourth week of life in one of six designated HSE paediatric CF centres, based on the baby’s address. The sweat test is considered the ‘gold’ standard for confirming the diagnosis of CF. Not all babies with CF will be detected by the newborn bloodspot screening programme. Milder variants of the condition may not be detected; some of these individuals may have a very benign clinical course which may not require treatment.

Note
- Newborn dried bloodspot IRT screen for CF is not suitable for babies/children over six weeks of age.
- Babies with meconium ileus (MI) should be strongly suspected of having CF and followed up accordingly, including CF mutations at birth. These babies may have a normal CF screen (normal IRT). **MI must be noted on the screening card.**
- The Irish CF mutational genetic panel screens for 38 mutations chosen to reflect the Irish population, therefore babies of non-Irish ethnic origin are at increased risk of non-detection within the Irish programme, particularly if parents are consanguineous.
3.2.6 Congenital Hypothyroidism (CHT)

Screening case definition: to detect babies with congenital hypothyroidism, with either thyroid agenesis or dysgenesis or dyshormonogenesis, based on the results of a Technetium-99m pertechnetate thyroid scan. The programme is not designed to detect minor aberrations of thyroid function in the newborn.

Unlike the other conditions, CHT is a congenital rather than an inherited condition, in the majority of cases. This is an endocrine condition, which results from failure of the thyroid gland to produce the hormone thyroxine. There are a number of different forms of the condition. Some babies may have a very small thyroid gland or no gland at all while others may not be able to make thyroxine. It is important to identify the cause; this can be done by performing a thyroid scan soon after the diagnosis has been made and usually before treatment has been started. Approximately 1 in every 2,300 babies born in Ireland may have the condition; early detection allows for early treatment and the prevention of symptoms.

The diagnosis is made by measuring blood thyroid stimulating hormone (TSH), high levels of which are suggestive of the condition. However, TSH rises in blood immediately after birth and then falls to normal by about the second day of life. This is one of the reasons why the routine heel-prick sample should not be taken before 72 hours after birth, otherwise a false-positive result for congenital hypothyroidism may occur.

The majority of babies with congenital hypothyroidism require thyroid hormone replacement. Some children will be reviewed by their endocrinology team between two and three years of age at which time a small number may be able to discontinue treatment under medical supervision. Otherwise treatment is for life and dose of thyroxine adjusted.

Compared to some of the other conditions, the frequency of false positive results for CHT is relatively high. Consequently the number of requests for repeat blood samples is also high. Possible reasons include:

- A transiently raised TSH concentration, which returns to normal in time. These babies may require a number of repeat samples to be collected.
- Hypothyroidism is more common in babies and children with Down Syndrome; as a result a disproportionate number of repeat samples may be requested from these babies as they may have a transiently elevated TSH level during the newborn period before developing hypothyroidism later.
- Babies, who have had surgery before having the screening sample taken, may have a transiently elevated TSH level. This may occur as some antiseptic skin preparations contain iodine which may be absorbed through the skin and cause transient hypothyroidism. This occurs more commonly in premature babies.

Note
- Preterm infants with hypothyroidism can have a delayed thyrotropin increase most likely because of immaturity of the hypothalamic – pituitary thyroid axis; these infants are at increased risk of being undetected in the screening process. A repeat samples should be collected at 37 weeks gestational age.
3.2.7 Medium Chain Acyl CoA Dehydrogenase deficiency (MCADD)

**Screening case definition:** to detect babies with MCAD deficiency (MCADD).
Not all babies with MCADD will be detected by newborn screening, patients carrying c.199T>C mutation in combination with c.985A>G or another mutation have been shown to have significantly lower acylcarnitine markers compared to other genotypes and there is a potential for false negative screening result. Also older infants with MCADD (greater than approximately one month of age) may have C8 levels below the screening cut-off and there is a potential for false negative screening result. Babies with carnitine depletion and very low concentration of free carnitine might not be detected by newborn screening. It must be noted that rarely, a baby may present clinically before results of a newborn screening are available.

MCADD is an autosomal recessive inherited defect of fatty acid oxidation due to deficiency of the enzyme medium-chain acyl-CoA dehydrogenase. This enzyme is required for the metabolism of medium-chain fatty acids and is necessary to enable the body to use its own fat reserves to produce energy in periods of fasting or stress.

Symptoms are not apparent at birth and about one third of cases of MCADD remain asymptomatic throughout life, however, symptoms can develop very quickly in affected infants who are not feeding well. Complications typically arise during periods of stress caused by an illness, fasting or vomiting, when the infant needs to break down stored fat quickly.

Episodes of metabolic decompensation can be prevented through avoidance of fasting, and monitoring of the infant to determine ‘safe’ time periods between meals and following a strict feeding schedule. MCADD mainly presents before the age of two years with a mean age of thirteen months, although neonatal presentations have also been reported.

Hypoglycaemia and a decompensated state develop which can result in serious life threatening symptoms including seizures and brain damage. When diagnosed within the newborn period and started on treatment, these babies grow up healthy and well. However, without treatment this condition may cause intellectual or physical disability or even death.

**Note**
- If a baby is on IV/Glucose or Dextrose a false negative screen may be reported for MCADD. It is imperative that this is noted on the screening card, and a repeat card taken when IV fluids discontinued.
3.2.8 Glutaric Aciduria Type 1 (GA1)

**Screening case definition:** to detect babies with GA1. The programme may not detect all babies with GA1, particularly those who excrete a low concentration of glutaric acid (low excretors) and those with very low concentration of free carnitine.

Glutaric aciduria type 1 (GA1) is an autosomal recessive inherited condition caused by a deficiency of the enzyme glutaryl-CoA dehydrogenase (GCDH). With this condition the body is unable to break down certain proteins properly. It is an organic acid condition as it can lead to harmful amounts of organic acids and toxins in the body. If left untreated it can cause brain defects or even death, however if the condition is detected early in life and proper treatment begins children with GA1 can lead healthy lives.

The enzyme GCDH is involved in the decarboxylation of glutaryl-CoA, which is an intermediate in the breakdown of the amino acids lysine, hydroxylysine and tryptophan. Defective catabolism causes the toxic accumulation of glutaric acid, 3-hydroxyglutaric acid, glutaconic acid and glutaryl carnitine.

Over 150 disease causing mutations have been identified; of these the R402W mutation is the most prevalent among Caucasians. Most mutations, including the R402W mutation, are associated with undetectable GCDH activity and excretion of high amounts of glutaric acid. However, mutations that lead to varying levels of residual GCDH activity and low excretion of glutaric acid have also been reported. Consequently, patients with GA1 can be divided into two biochemically defined subgroups low or high excretors, based on the levels of glutaric acid present in the urine.

About 70% of patients (including both low and high excretors) have an encephalopathic crisis, which is most common at around nine months, with 90% by age two years. These are usually precipitated about 1–3 days after onset of a non-specific intercurrent illness, gastrointestinal infection or pneumonia and lead to dystonia and dyskinesia as permanent sequelae but with relative preservation of the intellect.
3.2.9 **Adenosine Deaminase deficient Severe Combined Immunodeficiency (ADA-SCID)**

**Screening case definition:** To detect babies with ADA-SCID. Babies with the delayed or late onset forms of ADA deficiency may also be detected. The programme does not screen for other types of SCID.

ADA-SCID is a specific form of severe combined immunodeficiency (SCID) and is the most common cause of SCID in Ireland. It is an autosomal recessive condition which causes a deficiency of the enzyme adenosine deaminase (ADA). The lack of ADA enzyme is caused by biallelic mutations on the ADA gene. Approximately one in every 78,500 babies born in Ireland may have this condition. However, it is more common among babies born to Irish Traveller parents in whom the incidence is approximately 1 in every 1,200 births.

If not detected and treated early ADA-SCID can be life-threatening. The ADA enzyme is important for the breakdown of adenosine and deoxyadenosine. If the enzyme is deficient, adenosine and deoxyadenosine can accumulate and become toxic. Lymphocytes are particularly sensitive to the resulting toxic effect of deoxyadenosine, causing a marked depletion of T, B, and NK cells leading to SCID. As a result patients can present with frequent and severe infections such as pneumonia, often caused by an organism (Pneumocystis jirovecii) that does not cause illness in healthy individuals. ADA is active in other cells of the body, so patients with ADA-SCID can also have non-immune symptoms. There can be an impact on nervous, auditory, skeletal, pulmonary, hepatic cardiac and renal systems.

Early treatment with enzyme replacement therapy (PEG-ADA) can be used until definitive treatment (haematopoietic stem cell transplantation (HSCT)) is available. HSCT (with a matched donor), results in good overall outcome for the patient, gene therapy is an option for those without a matched donor. Long-term follow-up is important even for those who have been treated successfully, with careful monitoring of developmental, behavioural and psychological effects.

**Note:** Other conditions, if approved by the National Screening Advisory Committee (NSAC) and the department of Health may be added to the screening panel and sample takers will be notified well in advance of any change in practice.
4 Responsibility for ensuring all babies are offered newborn bloodspot screening

Newborn bloodspot screening is an integral part of the health service provided to newborn babies. Screening involves the co-operation of many agencies involved in sample collection, sample transport, sample analysis and recording of results to the referral and management of those babies diagnosed with one of the conditions. It is a complex process ensuring that all babies born in hospital or in the community are offered screening and followed-up until the screening process has been completed. 

Ref.: HSE Standard Operating Procedure for Maternity Hospitals/Units and Primary Care Services delivering the National Newborn Bloodspot Screening Programme.

Figure 2: National Governance Structure for Child Health Screening and Surveillance Programmes
Figure 3: National Newborn Bloodspot Screening Governance Structure
4.1 Responsibility of the Health Service Executive

The ultimate responsibility for ensuring that all babies are offered screening in accordance with agreed protocols and procedures rests with the HSE and the Assistant National Director of Health and Wellbeing – Public Health and Child Health, who chairs the National Newborn Bloodspot Screening Programme (NNBSP) Governance Group. The Director of the National Newborn Bloodspot Screening Laboratory (NNBSL) is responsible for the day to day coordination and management of the programme.

4.2 Responsibility and role of the NNBSP Governance Group

The NNBSP Governance Group is responsible for providing multidisciplinary advice to the HSE regarding technical and operational aspects of the programme and to the Director of Childhood Screening regarding strategic direction, policy and quality standards, funding objectives, legislation reviews and documentation relating to the programme, such as referral guidelines, manuals for practitioners, guidelines for storage, retention and use of residual bloodspots etc. The Governance Group is responsible for coordinating a quality assurance programme in partnership with health professionals and parents and monitors and facilitates improvements in the quality of the screening processes and their outcomes for parents and babies. The Governance Group is also responsible for supporting the development of information and training resources for health professionals and parents.

4.3 Responsibility of Community Healthcare Organisation (CHO) Child health leads

The CHO Child Health Leads are responsible for ensuring that all babies born and residing in their CHO are offered screening and that structures for the timely checking and recording of the test results are in place. The CHO Child Health Leads are also responsible for reporting newborn screening uptake and coverage to the NNBSP Governance Group.

4.4 Responsibility of Maternity Units and Maternity Hospitals

Directors of Nursing/Midwifery in maternity units/hospitals are responsible for ensuring that all babies born in hospital are offered screening. If the test is not performed in the maternity unit/hospital before discharge, hospital staff are responsible for ensuring that the baby is screened either by returning to the maternity unit/hospital or in the community, by informing Public Health Nurses (PHNs). The maternity unit/hospital informs the PHN Nursing Service of the discharge and the requirement for newborn bloodspot screening.

**Biohazard samples:** The maternity unit/hospital must inform the PHN Nursing service if the newborn screening sample is to be flagged as biohazard due to maternal infection, the nature of the infection does not need to be disclosed. It is sufficient to enclose the sample ‘fully dried’ in a biohazard bag, the outer envelope for posting should not be labelled biohazard.
4.5  **Responsibility of the public health nursing service in the CHO**

Directors of Public Health Nursing (PHN) are responsible for ensuring that the screen is carried out in their Local Health Area (LHO) following notification from the maternity unit/hospital on babies residing in their designated area. The Directors of PHN are also responsible for the timely recording of results in the newborn screening register including details of those babies who require follow-up, repeat sample or further investigation. Babies born in Northern Ireland but with an address in the Republic should have a screening card taken and sent to the NNBSL, Temple St. Dublin.

**N.B**  In the case where the maternity hospital/unit requests a repeat sample on a newborn and the NNBSL have already reported a ‘Not suspected’ result on that baby, the request from the maternity unit must be followed up. The NNBSL cannot override this request for a repeat from the maternity hospital/unit staff.

**N.B. Parents can request and are entitled to a copy of results from their PHN**

4.6  **Responsibility of GP’s, self-employed community and private midwives**

General Practitioners (GP), self-employed community midwives (SECMs) and Private Midwifery groups are responsible for performing the NNBSP screen in accordance with agreed HSE protocols and procedures and for dispatching the newborn bloodspot screening card to the NNBSL as soon as possible after collection in accordance with packaging transport regulations (see section 9). GPs rarely take heel prick samples and should contact the NNBSL for advice; they should also ensure they have an ‘in date’ newborn screening card if taking samples.

The dispatching of the sample is the responsibility of the sample taker and should not be delegated to the parents.

4.7  **Responsibility of parents/legal guardians**

Parent(s)/legal guardian(s) are responsible for their baby and their participation in the NNBSP. In the case of parent(s)/legal guardian(s) opting out of the NNBSP and having been informed by healthcare practitioners of the potential consequences to their baby in so doing, the responsibility for any possible adverse consequences of their decision lies with the parent(s)/legal guardian(s). They must be requested to signify their decision to opt-out in writing by completing the Opt-out Form (see Appendix 2). A copy of the completed form must be retained by the parent(s)/legal guardian(s) and a copy forwarded to the Directors of Midwifery/Nursing and Public Health Nursing, the NNBSL and the baby’s GP. If parent(s)/legal guardian(s) change their mind in the future, it is their responsibility to bring this ‘change of mind’ to the attention of the PHN or their GP.

If the parents refuse to complete the opt-out form, notice of this should be sent to the NNBSL by email. See appendix 2
4.8 Responsibility of the national newborn bloodspot screening laboratory (NNBSL)

The NNBSL is responsible for managing the programme on a day to day basis within the parameters and standards laid down by the Director of Childhood Screening and the NNBSP Governance Group. The NNBSL is responsible for overseeing the quality management system and reporting activities of the screening programme and ensuring that all screen positive cases are referred to the appropriate clinical care team within agreed standards and procedures and that a definitive diagnosis is ultimately made.

The NNBSL is responsible for providing on-going training and education where possible for all staff involved with the programme within agreed standards as required. The NNBSL also liaises with the individual clinical care groups to ensure that appropriate clinical audits are performed, thus optimising screening outcomes.

5 Consent for Newborn Screening

5.1 General overview

The Irish NNBSP screens for conditions that if not identified and treated promptly can have devastating consequences for the infant such as disability and possibly premature death. The newborn bloodspot screening or ‘heel-prick’ test should be offered to all infants through their parent(s)/legal guardian(s). All infants who are born in Ireland, or who enter the country (before the screen would have been performed in their country of origin) if they are under one year of age, are eligible.

As per current legislation and the 31st Amendment to the Constitution, the NNBSP Governance Group regards the best interest and welfare of the infant as the paramount consideration but is cognisant of the 2001 Supreme Court case of North Western Health Board v HW/CW. The 31st Amendment to the Constitution which involved the addition of Article 42A and governs the legal position around parental decision making has not yet been definitely tested by the Irish Courts.

The HSE National Consent Policy is also available for reference by staff and has recently been updated. Consent is also covered in the Nursing and Midwifery Board of Ireland Code of Professional Conduct and Ethics (2021).

5.2 Consent and responsibility for obtaining consent

Parent(s)/legal guardian(s) must be given the appropriate verbal and written information and sufficient time to make an informed decision. The HSE Parent Information Leaflets are available and should be given to parents during the third trimester of pregnancy by midwives and again when the newborn bloodspot screening sample is being taken. Parent(s)/legal guardian(s) should also be given the top page of the newborn bloodspot screening card which contains information about the NNBSP.
The sample taker is responsible for ensuring that appropriate signed consent is obtained and informing the Parent(s)/legal guardian(s) that by signing the NBSC they are confirming that:

- He/she received, read and understood the HSE Parent Guardian Information Leaflet – “What you need to know about Newborn Bloodspot Screening – heel prick”. There are translated versions of the HSE Parent Guardian Information Leaflet available on the HSE website for download [https://www2.hse.ie/screening-and-vaccinations/heel-prick-screening/heel-prick-screening-what-it-is.html](https://www2.hse.ie/screening-and-vaccinations/heel-prick-screening/heel-prick-screening-what-it-is.html). Translators can be used if required.
- The details of the infant on the NBSC are correct.
- They consent to the NBS sample being taken.
- They agree to the storage of the NBSC as per current Department of Health policy.

**N.B.** It is important to note that the National Newborn Bloodspot Screening Laboratory has a duty of care to analyse all newborn bloodspot screening samples they receive irrespective as to whether they are signed by a parent(s)/legal guardian(s) or not. It is the responsibility of the sample taker to ensure that signed consent is obtained when taking the sample.

### 5.3 Who can give consent

The HSE has published the revised National Consent Policy (2022) and Appendix 5 of the National Consent policy provides clarity as to who are a child’s legal guardians. The National Consent Policy (2022) notes that this is a complex legal position and the relevant provisions are set out in the Guardianship of Children Act 1964 as amended by the Child and Family Relationships Act 2015.

The Parent who signs the NBSC must be a legal guardian. Please note:

- Where a child’s mother and father are married at the time of birth both are the legal guardians and either can give consent to newborn bloodspot screening as per Section 6 of the Guardianship of Infants Act 1964.
- If a child’s mother and father are not married, the birth mother is automatically the legal guardian of the infant and can only sign the NBSC. The unmarried second parent may not be automatically the guardian of the infant, and may not be in a position within the timeframe for the NBS to have legal responsibility to sign the NBSC to provide consent.
- Since January 2016, the child’s father is an automatic legal guardian if he has lived with the child’s mother for 12 consecutive months including at least 3 months with the mother and child following the infant's birth. This may be applicable for cases of newborn bloodspot screening where a child may be screened up to the age of one year.
• If the birth mother is unavailable to sign the consent, i.e. through illness or hospital transfer, the unmarried second parent cannot sign the consent. In these cases, the sample taker should make every effort to contact the birth mother to get verbal consent and to document this in the relevant clinical notes/child health record. Written consent from the birth mother must be obtained at the earliest opportunity and forwarded to the NNBSL.

• If the birth mother is not contactable, for example due to severe illness, then the HSE must act in the best interest of the infant which would be to take the newborn bloodspot screening sample and inform the birth mother as soon as possible as to the decision taken and to record that in the child health record. If appropriate, this should ideally be in discussion with the second parent or primary care giver of the infant to ensure that they are aware of the need and benefit of newborn bloodspot screening.

• If the infant has been discharged home to the care of the second parent and the birth mother is too unwell to be discharged, the maternity hospital/unit should plan on the infant’s discharge that the second parent should bring the infant back into the hospital to obtain consent from the birth mother at the time of sampling.

• RPHNs/RMs arranging a house call to perform the newborn bloodspot screening must insist on the birth mother being present. Grandmothers or other relatives/friends cannot provide written consent.

• If a Midwife is taking the newborn bloodspot screening sample in hospital and the birth mother is not present on the ward, the midwife should return when the birth mother is present.

• Every effort should be made to obtain consent at the time of sample collection; this is especially relevant to cards taken in emergency situations and in the NICU. As per screening protocol when there is a screen positive for Cystic Fibrosis samples are referred to CHI Crumlin for CF genetic testing. Signed consent must be provided to release these genetic results which may have an impact on the baby’s family and possible future pregnancies. If a baby passed away and no consent was obtained, it is very difficult to go back to parents for retrospective consent.
5.4 Other circumstances

Where an interim care order is in place only the parent(s)/legal guardian(s) can provide consent.

If there is a full care order in place consent can be provided by the relevant health or social care provider. HSE National Consent Policy notes that it is good practice to seek consent of parent/legal guardian but not mandatory.

Other circumstances which more than likely will not apply to newborn screening due to the timing, although could be applicable for late screening up to the age of one year, but are worth noting include:

- **Adoption:** Where a child has been jointly adopted, the adoptive parents are the child’s legal guardians. However, adoption is unlikely to have been completed at the time that newborn bloodspot screening is due to take place (72-120 hours after birth) and the birth mother would be the legal guardian at that time.

- **Surrogacy:** Where a child is born through surrogacy in Ireland, the surrogate mother is the legal guardian at birth, until the commissioning mother/father are appointed as legal guardians. The surrogate mother, as birth mother, has legal responsibility for the newborn until the infant is legally adopted.
- For infants born to surrogates in Ireland it is permissible under the National Consent Policy for consent to be obtained from the surrogate mother by the sample taker by telephone/electronic means (Part 2 Section 4.2.2) if deemed necessary.
- If practicable, the surrogate mother may give consent prior to the infant being discharged but is must be made clear to the surrogate mother that she is consenting to the heel prick screening for the infant. The discussion that has taken place and the consent agreement must be documented in the healthcare record.
- If the commissioning father’s sperm was used in the surrogacy procedure, he may apply to the Court for a declaration of parentage; once granted, this would immediately entitle him to apply to the Court for guardianship. The commissioning mother, or a commissioning father whose sperm was not used in the procedure, may apply to the Court for legal guardianship one they/she has fulfilled the relevant legal requirements.
- **Surrogacy in another jurisdiction:** Under current Irish legislation, the surrogate mother, as birth mother, has legal responsibility for the newborn until the infant is legally adopted. This may mean that the birth mother is resident in another jurisdiction. There is currently no provision in Irish legislation allowing consent to be provided by the parents who bring the infant back into Ireland after birth abroad to a surrogate mother until legal adoption has taken place. This Procedure will be updated when there has been an update in the relevant Irish legislation around surrogacy abroad.
In respect of same sex couples, the infant’s biological parent is a legal guardian. The biological parent’s partner or spouse may apply to the Court to become a legal guardian in accordance with the requirements below. Where a same-sex couple has a child through donor assisted human reproduction (not including surrogacy) and has complied with the provisions of Part 2 of the Children and Family Relationships Act 2015, (i.e. they have used a recognised fertility clinic and have signed all the relevant consents and declarations) the spouse, civil partner or cohabitant of the parent will be the legal parent of the child. In this situation, the spouse or civil partner of the biological parent will automatically be a legal guardian. A cohabitant will be a legal guardian if they fulfil the residence requirement (i.e. have lived with the infant’s mother for 12 consecutive months including at least 3 months with the mother and the infant following the infant’s birth).

5.5 **Literacy difficulties**

If the parent(s)/legal guardian(s) has literacy difficulties they can be asked to make a mark on the newborn bloodspot screening card to indicate that they have been fully informed about the benefits and risks of newborn bloodspot screening.

5.6 **Right to opt-out of newborn screening**

Newborn bloodspot screening should take place as it is in the infant’s best interest. Parent(s)/legal guardian(s) do have the right to opt-out from the newborn bloodspot screening programme on behalf of their infant. If married, either parent can decide to opt out. If unmarried, only the mother can decide to opt out. However, they should be clearly counselled and fully informed about acting in the best interest of their infant’s health. If parent(s)/legal guardian(s) do decide to opt-out, it is essential that they are fully informed of the potential clinical consequences to their infant. Parent(s)/legal guardian(s) must sign the National Newborn Bloodspot Screening Programme Opt-Out form (available on [www.newbornscreening.ie](http://www.newbornscreening.ie)). Appendix 2. If the parents refuse to complete the opt-out form notice of this should be sent to the NNBSL.

Parent(s)/legal guardian(s) must be informed that they may change their mind in the future but that it is their responsibility to make their change of mind known to either the PHN or their GP. They must also be aware, that depending on the age of the infant at this point, it may alter how and for what conditions can be screened for.

- If parent(s)/legal guardian(s), in this case married parents, both disagree as to the provision of consent for newborn bloodspot screening the HSE National Consent Policy provides guidance on this in Section 3.2.2 (National Consent Policy 2022). All reasonable efforts should be made to recognise and respect their views as regard what is in the best interest of the child including when these views differ from those of the service provider. Where a second-opinion is sought by the parent(s)/legal guardian(s), this should be facilitated as far as possible by the service provided.
• Where parent(s) or legal guardian(s) refuse to consent to an intervention which the healthcare worker reasonably believes to be in the best interests of the child, every effort should be made to reach a consensus position as regards the best interest of the child. This may require involving one or more other healthcare workers, including the provision of independent second opinions, as well as mediation or other external supports (if these are available).

• If, having taken these steps, it is not possible for the healthcare workers and the parent(s) or legal guardian(s) to reach an agreement as to what is in the best interests of the child, it may be necessary to seek legal advice as to whether an application to the Court is required.

• In such a situation, the parent(s) or legal guardian(s) should be informed of their right to seek legal representation and to be heard in relation to the application. The healthcare worker has an obligation to act in the best interests of the child at all times. This means that if in the opinion of the healthcare worker the intervention is immediately required and there is no time to make an application to Court without exposing the child to an immediate risk of death or serious injury, the intervention should proceed notwithstanding the parental objection. In such a situation, the healthcare worker should record the basis for his or her evaluation that immediate intervention is required and the steps which they have taken on this basis.

5.7 Informing parent(s)/legal guardian(s) about the programme

Parent(s)/legal guardian(s) should be told:

• About the nature of the conditions included in the screening programme.

• If these conditions are detected soon after birth, treatment can be started early and significant handicap and possibly premature death can be prevented. Treatment varies depending on the disorder identified, for example dietary modifications or medication such as for the treatment of congenital hypothyroidism and for the prevention of CF related complications. Gene therapy and HSCT are the current treatments for ADA-SCID. Parents will be educated and supported by the respective clinical teams.

• That a further sample may be required, either to check the first result or because of an equivocal or borderline result or a technical problem in the first analysis, an insufficient quantity of blood collected, a contaminated sample or assay interference.

• A further sample may be requested if the identity of the baby is unclear; this can occur if the screening card is not filled in accurately – this is particularly important for twins, triplets etc. It is important to record on the card the rank of the baby, twin 2 of 2, recorded as 2/2.

• That parent(s)/legal guardian(s) of babies with a positive result will be contacted directly, usually by the maternity unit/hospital; clear instructions on how to proceed will be given.
Depending on the condition suspected, parent(s)/legal guardian(s) may be asked to bring their baby immediately to hospital, usually to CHI at Temple Street or CHI at Crumlin where the baby may be admitted for a period of time while treatment is commenced.

If the baby is suspected of having CF, they will be contacted by a CF Nurse Specialist from one of the six HSE designated paediatric CF Centres and asked to bring their baby in the following day for further tests.

5.8 Retention of the Newborn Bloodspot Screening Card

After screening, the NBS card is stored at a secure site by Temple St. on behalf of the HSE as part of the baby’s health record, after which time it will be disposed of as per HSE/Department of Health policy.

After screening the sample may be used to:

- Check the results of the screening test or to perform other investigations recommended by the child’s doctor, for which parent(s)/legal guardian(s) will be asked to give their signed consent.
- In the event of sudden unexpected death, consent may be obtained from the State Coroner.
- For quality assurance purposes and to help improve the screening programme as approved by the HSE. In such circumstances, all samples will be completely anonymised and it will not be possible to trace any result back to an individual baby.

5.9 Data protection legislation, GDPR and newborn bloodspot screening

Under an agreement between the NNBSP Governance Group and CHI at Temple Street the NNBSL manages the programme on behalf of the Governance Group on a day to day basis. CHI at Temple St acts as the Data Processors under the terms of the Data protection legislation on behalf of the NNBSP Governance Group, retaining baby demographic details and a copy of the results as part of the baby’s record.

The information required for newborn bloodspot screening is that collected and recorded on the NBS card, this information on baby’s feeds, transfusion status, date and time of birth and sample collection etc, plus identifiers is required for result interpretation and reporting.

Under GDPR regulations, in order for the NNBSL to be compliant with the data minimisation principle of GDPR there is a minimal amount of personal data that we require when screening card details are being completed and if further clarification or amendments required to what was originally recorded. The NNBSL cannot now accept birth notification or discharge summaries as details on parents(s) are included.
A Patient Detail Amendment form has been devised by the NNBSL for sample takers to complete if the need to amend any information on a newborn, refer to appendix 6, the current version of this form is available from info.newbornscreening@cuh.ie.

Access to the NNBSL ICT system is password protected and restricted to scientific and secretarial staff working in the NNBSL and to a third party who supplied and maintains the software. Maternity units/hospitals and local health offices have limited password protected access to data and results, only on babies born in their maternity unit/hospital or residing within their local health office through an electronic report handling system (eReports™).

5.10 Return or disposal of newborn bloodspot screening cards

Parent(s)/legal guardian(s) may request that the newborn screening card be returned or disposed of. It is the NNBSL policy to retain all samples for a minimum of six months before any return or disposal. Such requests must be made in writing to the: Risk Management department, CHI at Temple Street, Dublin D01 YC67. Requestors will be asked to provide proof of identity, e.g. a copy of their passport or driving license and a recent utility bill and a copy of the baby’s birth certificate.

Consent References

- Guardianship of Infants Act 1964
- Child Care Act 1991
- Thirty-first amendment of the Constitution (Children) Act 2012 – enacted April 2015
- Children and Family Relationships Act 2015
6 Sample Collection

Samples on all newborns must be collected by heel-prick irrespective of feed status, prematurity or clinical condition between 72 hours and 120 hours after birth, air dried and dispatched without delay to the NNBS Laboratory.

If the sample is collected outside this window (72-120 hours) it may adversely affect the result as follows:

Collected before 72 hours – it is essential that all babies should receive an adequate protein and lactose intake before the sample is taken, otherwise a false negative result may occur, for this reason, the sample is taken after 72 hours.

The TSH level (test used to screen for congenital hypothyroidism) may be transiently elevated immediately after birth; as a result, if the sample is taken too early (before 72 hrs.), some babies may have a false positive screen for congenital hypothyroidism.

If the sample is collected before 72 hours a repeat card will be requested.

Collected after 120 hours – because the programme includes screening for Classical Galactosaemia, MCADD and MSUD, it is essential that samples are not collected too long after birth, otherwise some babies may present clinically before the results of the screening test are available.

Exceptions to 72-120 hours window are pre-transfusion samples and high risk screens (see section 6.4)

- For babies at high risk of Classical Galactosaemia (Irish Travellers or a family history of Classical Galactosaemia) take a sample on day 1 for ‘BEUTLER’ test, in addition to a routine card taken at 72-120 hours.
- Take a pre-transfusion sample on any baby that is due to have a red blood cell (RBC) transfusion especially premature/low birth weight / sick babies and pre-surgery, then take the routine card at 72-120 hrs.
- If there is a family history of a metabolic condition seek advice from the NCIMD on these occasions (phone 01 878 4317), and always take a routine card at 72-120 hours.

6.1 Feeds at time of sample collection

6.1.1 Breast or formula fed babies
The NBS should be taken not earlier than 72 hours and not later than 120 hours after the infant’s birth. Infants should be established on full lactose and protein containing feeds for at least 24 hours before the newborn bloodspot sample is taken to minimise the risk of a false negative result. However babies at high risk of Classical Galactosaemia should not be given lactose/galactose containing feeds until the result of the Beutler test is available, please see sections 6.1.2 and 6.4.

Professional clinical judgement should be used in decision making around established feeding prior to taking the newborn bloodspot sample:
• For breastfed infants in the community, the Breastfeeding Observation Assessment Tool (BOAT) should be used to guide assessment of feeding and support professional decision making.
• For breastfed infants the maternity hospital/unit local individual feeding records (i.e. LATCH score) are available to guide assessment of feeding and support professional decision making.
• For infants on expressed breast milk/formula, the sample taker can review the infant’s intake over the previous 24 hours to aid assessment of feeding and support professional decision making.

Using professional clinical judgement, if an infant has not been feeding well, then:
• The sample taker should arrange to revisit the next day if it is still within the 72-120 hour window.
• Take the normal sample within the 72-120 hour window but an additional sample should be taken on or around Day 10.

Please contact the NNBSL (01 892 1804) for advice on feeds if unsure.

6.1.2 Babies on total parenteral nutrition, intravenous fluids and soya feeds

This should be clearly noted on the screening card. These babies may not be on any galactose/lactose or adequate protein containing feed and the screen could give a false negative result.

• TPN and soya feeds do not contain galactose, as a result babies on TPN or soya may produce a false negative result for Classical Galactosaemia (CGal). A Beutler test can be performed on these babies to out-rule CGal provided baby has not had a RBC transfusion. An RBC transfusion will invalidate the Beutler test.
• Babies on IV fluids may not have adequate protein and galactose intake and may result in a false negative for MCADD, amino acid disorders as well as CGal.
• CGal cannot be out ruled on transfused babies who have not had a pre-transfusion Beutler, until the baby is established on full lactose/galactose containing feeds for a period of time to indicate a possible raised galactose level.
• In the event where a baby remains on TPN/IV fluids and a Beutler could not be performed due to RBC transfusion, the baby should be monitored for clinical and laboratory signs (prolonged clotting times and raised liver enzymes) of Galactosaemia when being established on lactose/galactose containing feeds.
• If a baby is on IV/Glucose or dextrose a false negative screen may be reported for MCADD. It is imperative that IV fluid intake is noted on the screening card, and a repeat card to be collected when IV fluids discontinued.

6.1.3 Feeds protocol for high risk (sibling) MCADD screens

It is essential to ensure that the baby maintains a good milk intake until results are available. If baby is well it should be bottle fed every 3 hours or if breast fed every 2-3 hours during day time and every 3 hours at night (at least 10 minutes on the breast). Exclusively breast fed babies are particularly at risk in the first few days when the supply of breast milk is poor; top up feeds of expressed breast or formula milk may be necessary until a good milk supply is established. Seek advice from the metabolic clinical team in Temple St. (01 8784317).
If oral feeds are not tolerated, or if the baby is unwell in any way, urgent referral should be made to a Metabolic Paediatrician for review and consideration of IV glucose.

**N.B.:** If a baby is on IV/Glucose or dextrose a false negative screen may be reported for MCADD. It is imperative that this is noted on the screening card, and a repeat card collected when IV fluids discontinued.

### 6.2 Babies receiving red blood cell (RBC) transfusions

- If a RBC transfusion is scheduled to be given before the routine 72-120 hr. screen is taken, a pre-transfusion sample should be collected to perform a Beutler test to out-rule CGal.
- A newborn screening sample must also be collected between 72-120 hrs. after birth regardless if the child has had a further transfusion. Do not delay this 72-120 hr. sample due to transfusions.
- For any further cards collected on these transfused babies, please allow 72 hrs. to pass post any further transfusions before taking any more cards, unless specifically requested by the laboratory or clinical team.
- If the baby received an intrauterine transfusion, this should be clearly noted on the screening card, as this will invalidate the result of the Beutler test and could give a false negative screen result.

**NB.** A RBC transfusion invalidates the Beutler test for Classical Galactosaemia as the enzyme measured is in the red cells.

### 6.3 Preterm and low birth weight babies

- All premature babies should have a pre-transfusion sample taken if a RBC transfusion is planned or likely, to out-rule Classical Galactosaemia. These babies may not be established on full feeds for some time (may be on TPN and/or IV fluids) and a false negative may be reported. A routine sample should be taken between 72-120 hours after birth.
- Further samples should be collected at regular intervals e.g. as a guideline 1 week, 2 weeks, 4 weeks and term-corrected gestational age. On some occasions additional samples may be requested by the NNBSL or Clinical team.
- Preterm infants with hypothyroidism can have a delayed thyrotropin increase most likely because of immaturity of the hypothalamic – pituitary thyroid axis; these infants are at increased risk of being undetected in the screening process if repeat samples are not collected at term corrected gestational age. Please call the laboratory for advice if unsure (01 892 1804).

### 6.4 High Risk Screening for Metabolic Disorders

**Guidelines for siblings or children of known cases of metabolic disorders**

In all cases note family history of disorder on screening card e.g. sibling, parent or other extended family member. Please see next page for details.
High Risk Screening Guidelines for siblings or children of known cases*

Contact Telephone Details:
NCIMD National Centre for Inherited Metabolic Disorders, for clinical advice: 01 8784317
Metabolic laboratory CHI at Temple St., for sample requirement advice: 01 8784458/ 5557/ 4724
NNBSL CHI at Temple St. for sampling advice : 01 8921804

*For GAL, PKU, MSUD, HCU, MCADD and GA1 follow-up. Refer to appendix 7

<table>
<thead>
<tr>
<th>Condition</th>
<th>Sample to be taken</th>
<th>When to take - time after birth</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PKU</strong></td>
<td>Lithium heparin liquid sample (2 mls)</td>
<td>72-120 hours</td>
</tr>
<tr>
<td></td>
<td>Routine NBS card</td>
<td>72-120 hours</td>
</tr>
<tr>
<td></td>
<td>If the 72 hrs. following birth is due to fall on a Saturday, then we recommend that the liquid sample is taken and sent to the Metabolic laboratory in Temple St on the Friday morning and laboratory phoned in advance, in order to avoid parental anxiety over the weekend</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NBS Card</td>
<td>Day 10</td>
</tr>
</tbody>
</table>

| **HCU**   | Lithium heparin liquid sample (2 mls) for Methionine and Total Homocysteine, separate within 15 mins and freeze immediately (contact metabolic laboratory for details 01 8784724) | 72-120 hours |
|           | Routine NBS card   | 72-120 hours                  |
|           | Lithium heparin liquid sample (2 mls) for Methionine and Total Homocysteine, separate within 15 mins and freeze immediately (contact metabolic laboratory for details 01 8784724) | Day 10 |

<p>| <strong>MSUD</strong>  | Lithium heparin liquid sample (2 mls), separate promptly &amp; refrigerate/ freeze within 2 hours | Day 1 after 2nd feed, then daily until established on full feeds |
|           | Urine or blood for ketones | Daily |
|           | Routine NBS card | 72-120 hours |
|           | NBS card at Day 10 or Lithium heparin liquid sample, separate promptly &amp; refrigerate/freeze within 2 hours | Day 10 |</p>
<table>
<thead>
<tr>
<th>Condition</th>
<th>Sample to be taken</th>
<th>When to take - time after birth</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Classical Galactosaemia</strong></td>
<td>NBS card for Beutler test. Advise lactose/galactose free feeds (e.g. soya feeds) only, until results of Beutler test available. Cord blood sample is not suitable, record if baby has had a red cell transfusion or intrauterine transfusion as this will invalidate the Beutler test.</td>
<td>Day 1 Beutler</td>
</tr>
<tr>
<td></td>
<td>Routine NBS card</td>
<td>72-120 hours</td>
</tr>
<tr>
<td><strong>MCADD</strong></td>
<td>It is extremely important that babies at risk of MCADD are tested at the earliest opportunity. Pregnancy should be discussed with the metabolic clinical team NCIMD for careful management at birth to minimise risk of decompensation. Management at birth may depend on presentation of previous sibling. Send DBS Acylcarnitine on metabolic screening card or NBS card if not available. Write ‘Family History of MCADD’, indicate if baby on IV fluids, glucose/ dextrose</td>
<td>24-48 hours</td>
</tr>
<tr>
<td></td>
<td>N.B. It is essential that the baby maintains a good milk intake until results are available, see section 11.5.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urine Organic acid - 5 mls fresh sample (frozen immediately at -20°C) with no preservative</td>
<td>24-48 hours</td>
</tr>
<tr>
<td></td>
<td>Routine NBS card</td>
<td>72-120 hours</td>
</tr>
<tr>
<td></td>
<td>DBS Acylcarnitine on metabolic screening card or NBS card if not available</td>
<td>Day 10</td>
</tr>
<tr>
<td><strong>GA1</strong></td>
<td>DBS Acylcarnitine on metabolic screening card or NBS card if not available. Write ‘Family History of GA1’</td>
<td>24-48 hours</td>
</tr>
<tr>
<td></td>
<td>Urine Organic acid - 5 mls fresh sample (frozen immediately at -20°C) with no preservative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Routine NBS card</td>
<td>72 – 120 hours</td>
</tr>
<tr>
<td></td>
<td>DBS Acylcarnitine on metabolic screening card or NBS card</td>
<td>Day 10</td>
</tr>
</tbody>
</table>

In all cases note family history of disorder on screening card.
6.4.1 Family history of a metabolic disorder in extended family

If there is a history of a metabolic disorder within the extended family other than a sibling, this should be clearly stated on the screening card to include the name of the disorder, in such circumstances please contact the NNBSL or NCIMD Temple Street for advice.

6.4.2 Consanguinity and Endogamous populations

Twenty percent of the world's population practice consanguinity. This is a traditional practice in the Middle East, Pakistan, Bangladesh and North Africa. Consanguineous marriages/unions and couples who come from the same endogamous (small close) community (e.g. Irish Travellers and Roma) have an increased risk of having a child with a rare medical condition (specifically autosomal recessive disorders). There are certain autosomal recessive disorders that occur more commonly in different countries or endogamous populations. The Department of Clinical Genetics in CHI at Crumlin can give advice on these disorders, the likely risk and genetic tests to consider in high risk groups.

6.4.3 Maternal phenylketonuria (PKU)

Phenylalanine is actively transported across the placenta; as a result the blood level in the foetus is about twice that of the mother. Therefore, women who themselves have PKU, should plan conception so that their condition is under optimal control at the time of conception. Regular and frequent monitoring of blood levels of phenylalanine and tyrosine are required throughout pregnancy in order to safeguard the well-being of their foetus. Following the birth of the baby a liquid sample should be taken from the baby at the same time as the newborn screening sample (72-120 hrs.) and a repeat screening sample on day 10 of life.

6.5 High Risk Screening for Other Disorders

Cystic Fibrosis, Congenital Hypothyroidism and Adenosine Deaminase Deficient Severe Combined Immunodeficiency

Cystic Fibrosis

For a child born to a parent with CF, where no prior CF genetic testing has been carried out for the parents or the pregnancy, a blood sample from the baby and both parents should be sent (with parent(s)/legal guardian(s) consent), to the Department of Clinical Genetics in Children’s Health Ireland, Crumlin. For a sibling of a known CF case, an EDTA blood sample should be sent directly by the maternity unit/hospital (if parent(s)/legal guardian(s) request/consent), to the Department of Clinical Genetics in CHI at Crumlin, clearly stating the name and DOB of the affected sibling. A routine NBS card must still be taken at 72-120 hours.
**Congenital Hypothyroidism**

Thyroid Function Tests (TFTs) liquid sample should be taken at Day 3 and analysed locally. Sample takers should consult local laboratory for sampling guidelines; lithium heparin or serum. A routine NBS card must still be taken at 72-120 hours.

**Adenosine deaminase deficient severe combined immunodeficiency**

All parents of infants diagnosed with confirmed ADA-SCID are referred for genetic counselling after the diagnosis. In the event of future pregnancies, once the Immunology team is informed, information on relevant screening at birth is shared with the mother’s obstetric team and the relevant neonatal/paediatric team.

To screen newborn siblings of a known ADA-SCID case, take 2mls of blood in EDTA (ambient temperature, do not freeze) for flow cytometry and ADA enzyme analysis at birth. This should be sent immediately to the Immunology Laboratory, Lab Med Department, St James' Hospital, James' Street, Dublin 8, D08 NYH1.

The department of immunology and infectious diseases in CHI Crumlin should be informed once the infant is delivered and results discussed with the Paediatric Immunologist once available. A routine NBS card must still be taken at 72-120 hours.

6.6 **Babies born to immigrant parents or refugees**

6.6.1 **Arriving before NBS has been performed in country of birth**

All babies and infants of immigrant parent(s)/legal guardians, up to one year of age, who arrive in Ireland before any newborn screening test has been performed, should be screened for all the conditions on the Irish panel (excluding CF if baby over six weeks of age). Screening for CF by measuring blood IRT is not reliable for any infants over six weeks of age. See section 6.8.

6.6.2 **Arriving after NBS screen has been performed in country of birth**

The sample taker should be aware that many countries including Northern Ireland’s newborn screening programme do not include screening for Classical Galactosaemia or ADA-SCID. If there is clinical concern of Classical Galactosaemia, then the Beutler test should be requested on a dried bloodspot. The full screening panel (excluding CF if baby over six weeks of age) can be performed on babies under one year of age.

Decision to screen is a local clinical decision, dependent on family history and country of origin of parents. Often a venous sample is taken and spotted onto the card as it may not be possible to take a heel prick sample, it is imperative that this sample is whole blood and has not been collected in a tube with any preservative (such as EDTA, lithium heparin etc.).

If there is no documented evidence in a child’s medical records that screening was performed please contact the NNBSL who may have a record and can advise.
6.7 Babies presenting with meconium ileus at birth

Meconium ileus is a common complication in babies with CF, occurring in about 18% of all CF babies born in Ireland. Not all these infants present with a raised blood IRT (i.e. a positive CF screen) from the NBS screen. Therefore, CF should be considered in all babies who present with meconium ileus within the first days of life. An ETDA sample should be collected and sent directly by the maternity unit/hospital to the Department of Medical Genetics, CHI at Crumlin for CF mutation analysis, giving full clinical information.

The routine NBS sample should be taken at 72-120 hours to screen for the other conditions. **Meconium ileus should be noted on card.**

6.8 Infants over six weeks who missed CF screening due to programme issue

Children who have missed the 72-120 hours window for newborn bloodspot screening for logistical reasons can have their screen completed without delay when issues identified.

Immunoreactive trypsinogen (IRT) the screen for cystic fibrosis (CF) is not suitable if the infant is over six weeks of age. This applies to premature infants as well as term infants. Beyond six weeks of age the IRT value is not interpretable and a bloodspot sample is invalid for the purpose of CF screening.

Therefore, for children greater than six weeks of age who were missed or there was a problem with the sample, or the testing, such that no result for CF NBS is available, a sweat test should be performed to rule out CF.

The sweat test should be performed in one of the six specialist CF centres involved in accepting children for assessment as per the CF NBS programme. The following steps should be undertaken:

1. The individual aware of or concerned that a child has not been screened for CF as part of the CF NBS programme should inform the National Newborn Bloodspot Screening laboratory (NNBSL) in CHI at Temple St, Dublin.

2. The NNBSL should collect the relevant details of the infant involved, and the details of why screening was missed, and then contact the specialist CF centre nearest the baby’s geographic catchment area to request a sweat test.

3. Contact with the specialist CF Centre should use the existing lines of communication for the CF NBS programme; i.e. a telephone call to the CF clinical nurse specialist (CNS) followed by written details. This will be carried out by the NNBSL laboratory.

4. The CF CNS will organise a sweat test and review by a CF Consultant as per the usual procedure for the CF NBS programme.

5. The specialist CF centre will provide the results to the parents/legal guardians and NNBSL as soon as they are available.
6. The NNBSL will inform the individual who highlighted the case that the infant has been assessed and will inform the maternity unit and the Director of Public Health Nursing in that area.

The procedure as described above does not apply to infants who had newborn bloodspot screening performed in another country which did not include CF NBS, and then moved to Ireland at a later date. These children should not be screened for CF, but should have a sweat test performed only if clinically indicated, such as if they develop clinical features, or have a strong family history of CF. If a sweat test cannot be performed genetic analysis to be offered following parental consent.
7 Recording of Information

7.1 UPI, hospital codes and correct recording of LHOs

Correct use of UPI: Until the HSE’s Individual Health Identifier (IHI) is introduced nationally, the unique perinatal identifier (UPI), issued by the maternity units/hospitals must be used to track each baby through the NBS process. The UPI consists of the three digit hospital inpatient inquiry (HIPE) code of the maternity unit/hospital of birth (see Table 2.) followed by the Healthcare Record Number (HCRN) of the baby. Babies born either at home or in a maternity hospital outside Ireland will be issued with a UPI by the Director of Public Health Nursing in the area in which the birth is registered following notification of the birth.

A baby only has one UPI and this must be used on all screening samples sent to the laboratory to track the baby through the screening process. If a baby is transferred to another hospital the HCRN of the transfer hospital must also be included in the appropriate section of the screening card, see below for an image of the screening card. The onus is on the birth hospital transferring the baby to ensure that the baby’s UPI is included on all referral/transfer correspondence. If the UPI is not provided, the receiving hospital must contact the birth hospital to obtain the UPI. They should not generate their own UPI.
Accuracy in recording of Local Health Office (LHO)

All results are issued via eReports to the Local Health Office that is recorded on the card. If an incorrect LHO is recorded the result will be sent to the incorrect area. This can lead to delays in follow up of babies who may need a repeat sample taken and also is problematic for Liaison PHNs who are tracking results of babies from their LHO area.

Examples of some errors

- Community Healthcare Organisation (CHO) recorded incorrectly instead of LHO, e.g. CHO Area 5 recorded which covers four LHOs Carlow/Kilkenny, Waterford, Wexford and South Tipperary, this can be confused with CCD5 in Dublin.

- Address not filled in correctly to help identify area e.g. Adamstown recorded as address but no county noted.

- Baby’s address recorded as “Apt 4, Dublin Road” with no further detail provided. A full address with LHO is required.

- There are four LHO areas in Cork: North Lee, South Lee, North Cork and West Cork but parts of Mitchelstown, Co. Cork are in Limerick. There are other examples of addresses on county borders that are in a neighbouring LHO.

**Eircode**: the Eircode should be recorded in the appropriate box. This will in time be linked to the Local Health Office (LHO) to verify that the LHO on the sample is correct.

Table 2 HIPE Code Numbers for 19 Maternity Units/Hospitals

<table>
<thead>
<tr>
<th>HIPE Code</th>
<th>Maternity Hospital / Unit</th>
<th>HIPE Code</th>
<th>Maternity Hospital / Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>201</td>
<td>Midland Regional Hospital Portlaoise</td>
<td>724</td>
<td>Cork University Maternity Hospital</td>
</tr>
<tr>
<td>202</td>
<td>Midland Regional Hospital Mullingar</td>
<td>726</td>
<td>Kerry University Hospital, Tralee</td>
</tr>
<tr>
<td>301</td>
<td>University Maternity Hospital Limerick</td>
<td>800</td>
<td>University Hospital Galway</td>
</tr>
<tr>
<td>402</td>
<td>Cavan General Hospital, Cavan</td>
<td>802</td>
<td>Mayo University Hospital</td>
</tr>
<tr>
<td>500</td>
<td>Letterkenny University Hospital</td>
<td>919</td>
<td>Portiuncula Hospital, Ballinasloe</td>
</tr>
<tr>
<td>501</td>
<td>Sligo University Hospital</td>
<td>922</td>
<td>Our Lady of Lourdes Hospital, Drogheda</td>
</tr>
<tr>
<td>600</td>
<td>Waterford University Hospital</td>
<td>930</td>
<td>Coombe Women’s Hospital, Dublin</td>
</tr>
<tr>
<td>601</td>
<td>St. Luke’s General Hospital Kilkenny</td>
<td>931</td>
<td>National Maternity Hospital, Holles St, Dublin</td>
</tr>
<tr>
<td>605</td>
<td>Wexford General Hospital</td>
<td>932</td>
<td>Rotunda Hospital, Dublin</td>
</tr>
<tr>
<td>607</td>
<td>South Tipperary General Hospital</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
7.2 Recording of results of newborn blood spot screen

The following steps must be adhered to, to ensure that adequate records are maintained in the hospital of birth in order to identify any baby who has not been screened before discharge:

a) A person should be nominated by the hospital to take responsibility for checking records;
b) Details of each baby should be recorded in a single register;
c) The register must indicate whether or not the test was performed and if there is follow-up required;
d) When the results of the test are returned from the NNBSL, the entry should be ticked in a different colour pen (if a manual procedure is used) or entered into the electronic register – therefore, any case where there is no report received from the NNBSL is noticeable at a glance and can be followed up;
e) The person who checks the register to identify possible omissions should initial the entries to indicate that he/she has undertaken the exercise.

Parents can request and are entitled to a copy of results from their PHN

7.3 Discharges from hospital before NBS

The nurse/midwife discharging a baby from hospital before the screen has been carried out must ensure that the mother understands the importance of the screen and when the screen should be done.

If it is not appropriate to carry out the screen before discharge from hospital, the nurse/midwife should ensure that the baby is screened either:

- by returning to the hospital
- or in the community. The nurse/midwife should notify the DPHN that the baby has been discharged.

The DPHN in the LHO in which the parent(s)/legal guardian(s) live is responsible for ensuring that babies, discharged from hospital prior to having the screen performed, have the screen carried out.

Weekend sampling varies across the country as not all areas provide a weekend PHN service and babies may have to return to the hospital for the sample to be taken.
7.3.1 Newborn bloodspot screening to be performed by PHN

If the screen is to be performed by a PHN, the following procedures should be followed:

(a) The ward manager should ensure that the appropriate DPHN has been notified that the screen is to be carried out. The Director should be provided with the full details of the baby, including the UPI. They should also be informed if either the baby or mother is being investigated for an infectious disease.

(b) The Director of Public Health Nursing should:
   - Keep a register of requests from hospitals;
   - Request the appropriate PHN to perform the screen and to send the sample by registered post (and obtain a receipt of postage) to the NNBSL, CHI at Temple St. Dublin D01 YC67.
   - Notify the maternity unit/hospital where the birth took place that the screen has been carried out.

The NNBSL send a copy of all results electronically to both to the maternity unit/hospital and to the LHOs. For this reason, it is essential to ensure the LHO is correct.

If results are received back to an LHO that a baby does not reside in, an 'incorrect location form', can be completed and location changed, forms are available on the website or see appendix 1. The report will then be resent to correct area.

7.3.2 Newborn screening performed by GP or independent midwife

If the screen is to be performed by a GP or an independent midwife, the following procedures should be followed:

(a) The DPHN must contact the GP or the independent midwife to ensure that the screen will be performed and sample sent by courier/registered post (retain proof of postage) to the NNBS Laboratory. It is the responsibility of the GP/independent midwife to arrange the transport of the sample; this should NOT be delegated to the parents.

(b) The NNBSL will send a copy of results to the maternity unit/hospital, the DPHN and to the GP / independent midwife if noted on the NBS sample.

(c) The GP/ midwife must contact the DPHN in cases of non-attendance by the parent(s)/legal guardian(s).

In the situation where a family have moved out of the area before the screen was performed, the DPHN must be informed of the circumstances as early as possible so that alternative arrangements may be made.

NB. It is not normal practice for GPs to take NBS samples and they do not hold a supply of cards. GPs should contact the laboratory for advice if performing newborn blood spot screening.
7.4 Transfer from maternity unit/hospital to another hospital

The nurse/midwife responsible for the transfer of a baby from a maternity unit/hospital to a tertiary referral paediatric unit MUST inform the receiving unit of the status of the NBS and give them the baby’s UPI.

The paediatric unit must have written procedures for:

- Performing the screen between 72-120 hrs. after birth
- Documenting that the sample has been collected
- Have a valid, in date card to collect sample on
- Be aware of necessity for signed consent
- Be informed about taking pre-transfusion samples
- Sending the sample to the NNBSL
- Recording the results in the baby’s medical records
- Informing the maternity unit/hospital of the results of the screen and any request for repeat sampling or follow-up action

Transfer Hospitals: If a sample is taken in a transfer hospital, and this information is recorded on the screening card, the transfer hospital also receives a copy of the result. If a baby was transferred to another hospital after a sample is collected, the hospital where the sample was taken has responsibility to inform the transfer hospital re repeat sample.

Babies admitted to SCBU: Responsibility to ensure initial or repeat samples are taken lies with hospital of birth. Each maternity hospital has two logins for eReports, as do community care and it is the responsibility of those checking results to inform SCBU if initial or repeat screen required, as SCBU will not have access to electronic reports.
8 Procedure for taking the routine blood sample

The blood sample should be taken between 72 hours and 120 hours after birth

8.1 Completion of the newborn bloodspot screening card

Ensure that the NBS card has been completed in full and that all the information is correct and legible, including the name of the baby. Particular care should be taken to distinguish twins, triplets etc. The NBS card must be signed by a parent(s)/legal guardian(s) before the sample is collected to show evidence of consent.

Changes to data collected on screening cards: In September 2020 changes were made to data collected on screening cards as a result of specific feedback from Public Health Nurses, Midwives and the NNBS Laboratory in Temple Street. Existing screening cards in stock can still be used provided the expiry date has not passed. The changes and rationale are outlined in the table below:

<table>
<thead>
<tr>
<th>Change</th>
<th>Rationale/Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Contact email address for the National Newborn Bloodspot Screening Laboratory has been added to the contact details.</td>
<td>For ease of contact with the Newborn Bloodspot Screening Laboratory.</td>
</tr>
<tr>
<td>2. Birth weight now needs to be recorded to 3 decimal places, where available.</td>
<td>Birth weight recorded to 3 decimal places, if available, is required to ensure optimal performance and on-going quality assurance of laboratory methods.</td>
</tr>
<tr>
<td>3. Additional type of feed/fluid has been added – Glu/Dex = Glucose/Dextrose</td>
<td>If a baby is on Glucose/Dextrose IV fluids when the bloodspot sample is taken, this could give a false negative result for Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD). Therefore it is very important that the laboratory is made aware of babies on Glucose/Dextrose fluids.</td>
</tr>
<tr>
<td>4. Mothers Surname has the addition of ‘IF DIFFERENT FROM BABY’S”</td>
<td>On occasion the surname of the parent providing consent can differ from the baby’s surname. The mother’s surname needs to be queried to ensure consent is provided by the appropriate person.</td>
</tr>
<tr>
<td>5. Location sample taken is now either ‘Community/Home’ or ‘Hospital’.</td>
<td>‘Early Transfer Home’ has been removed as there were very few cases of this. ‘Community/Home’ refers to any sample taken outside the Maternity Hospital/Unit setting; i.e. for samples taken at home, a clinic or local health centre.</td>
</tr>
<tr>
<td>6. The ‘hospital ward’ field has been changed to ‘If transfer state hospital’.</td>
<td>This is to capture cases where a baby has been transferred to another hospital and the initial or repeat sample may be taken at that hospital. This is not the birth hospital.</td>
</tr>
</tbody>
</table>
7. Parent’s ethnicity.

Ethnicity is highly relevant with respect to newborn bloodspot screening, as different ethnic groups will have different prevalence of the eight conditions that are currently screened for in Ireland. Ethnicity data is required to ensure equity of the programme and inform programme reviews.

Sample takers are requested to record a code on the screening card. The list of ethnicity codes are included on the back of each screening card and are consistent with the codes used by the Central Statistics Office (CSO) when carrying out the national census.

1 = White Irish
2 = White Irish Traveller
3 = Any other White background
4 = Black or Black Irish – African
5 = Black or Black Irish – any other Black background
6 = Asian or Asian Irish – Chinese
7 = Asian or Asian Irish – any other Asian background
8 = Other, including mixed background – specify.

It is noted that space is at a premium on the screening card so if the ethnicity code is 8 - Other please try to record the ethnicity on the screening card in the space provided.

Further details around ethnicity are detailed below

- Ethnic Equality Monitoring

According to the HSE’s National Office for Social Inclusion a person’s ethnic group or cultural background, country of birth, religion and language spoken can have an effect on their health. Collecting this information from all who use the health service will help to ensure that the health services provided are right for everyone.

This is particularly important for newborn bloodspot screening where the aim is to detect babies that are at high risk of having a serious inherited condition. There is very little knowledge of the prevalence of these conditions in Ireland amongst our increasingly multi-cultural society.

Collecting the ethnicity of parents of babies screened will enable the screening programme to determine the birth prevalence of these inherited conditions in various ethnic groups and is a first step to understanding the short and long term disease management needs faced by affected communities, especially ethnic groups that may be more affected by particular conditions.
• **Resources available for staff on Ethnic Equality Monitoring**

The HSE National Office for Social Inclusion has developed a range of resources to support putting ethnic equality monitoring in place in the Irish health service.

- An online training module called First Steps in Ethnic Equality Monitoring which is available to all HSE staff on HSELand. This training is aimed at:
  - Hospital and community healthcare staff involved in collecting personal data from service users
  - Directors and managers of healthcare services
  - Data analysis personnel
  - Health and/or social care researchers
  - Staff of community or voluntary sector organisations

- A public information leaflet and poster have been developed which explains why the health service requires information about a person’s ethnic group; religion; country of birth and language – examples are included in this appendix and all these resources are available at: [https://www.hse.ie/eng/about/who/primarycare/socialinclusion/intercultural-health/ethnic-equality-monitoring/](https://www.hse.ie/eng/about/who/primarycare/socialinclusion/intercultural-health/ethnic-equality-monitoring/)

---

### 8.2 **Equipment required**

- Sterile lancet (metered tip no more than 2.5 mm in depth)
- Latex free gloves
- Gauze
- Newborn bloodspot screening card, card must be in date, check expiry
- Envelope for dispatch to lab, water resistant and tear-proof (Tyvek or equivalent envelope)
8.3 Technique for Sample Collection

a) Ask the parents/legal guardians to keep the baby’s feet warm prior to sampling, by applying two sets of socks or placing a set of socks beneath the babygro.
b) Read the instructions printed on the back of the NBS card.
c) Explain to the parent(s)/legal guardian(s) the reason for the screen and its importance to the baby’s well-being.
d) Obtain signed consent (See Section. 5).
e) Tear off the top information sheet and the <Parent Copy> from the NBS card and give it to the parent(s)/legal guardian(s), along with the Parent Information leaflet, retain the <Nurse Copy> for filing in the child record.
f) Ensure <Laboratory Copy> remains attached to the card.
g) Assemble the equipment and put on gloves. Do NOT touch bloodspot rings on the card with gloves before, during or after the sample is taken. Ensure there is no contact with Vaseline or other creams. Latex interferes with Beutler test and may cause a false positive result. Latex free gloves are to be used when carrying out the NBS.
h) Preferably take the sample from the baby while the Parent/legal Guardian cuddles the baby on their knee or on their shoulder; this not only assists you but also comforts the baby. It also allows the Parent/legal Guardian the opportunity to ask questions about the screen.
i) Ensure that the heel is warm. Do not use active heating such as a hair dryer.
j) Place a paper towel on the lap of the individual holding the baby.
k) Ensure that the heel is visibly clean and warm. The skin may be gently rubbed for 1-2 minutes to increase blood supply if deemed necessary. Never use any external warming source (e.g. hairdryer, warm water). This introduces a risk of thermal burns and/or scalds.
l) Routine cleansing of the heel is not required. However, if the heel is visibly dirty or soiled it can be cleaned with gauze soaked in cool sterile water. Ensure that the heel is completely dry before taking the sample. Do not use alcohol or baby wipes as they may interfere with sample results or cause serum rings. Allow the heel to air dry completely.
m) Encircle the heel with finger(s) and thumb and squeeze gently until the skin looks taut and suffused with blood.
n) Press the lancet firmly against the side of the ball of the heel and trigger the sterile lancet.
o) Hold the foot downwards and gently massage heel to encourage blood flow.

p) Wipe away the first drop of blood and allow another large drop to form. (The first drop may be a diluted blood drop). Touch the circles marked on the NBS card gently to the hanging drop of blood so that the blood soaks through from the back of the NBS card to the front:
   • blood drops must soak through from the back to the front of the card, filling all circles completely;
   • check that the blood has soaked completely through the circle on the front as well as the rear of the card;
   • do not press/squeeze the bloodspot to ‘force’ it through the NBS card as this can compress the blood cells and may require repeat.

The Sample Taker will ensure sufficient blood is taken to meet the requirements to completely fill the four bloodspots circles on the card.

q) Wipe away excess blood with gauze. Press clean gauze firmly onto the wound until bleeding stops.

**N.B.** It is not recommended that a plaster is used as this may be a choking hazard if swallowed.

r) Ensure that the NBS card is air-dried before putting it into the envelope. Do not use excessive heating as this may invalidate screen. Failure to fully dry the bloodspot before placing it in the envelope may result in serum rings, invalidating the sample and thus requiring a repeat sample to be taken.

s) If a repeat sample is required for one test only, then two well-saturated bloodspots are sufficient, ensure sample is saturated through from back to front.

t) Parents/legal Guardians should be informed of the reason for a repeat sample if repeat requested.

u) The blood spots collected do not need to be the outside spots; they can be any of the four spots outlined on the card.

See figure 4 for a visual example of both a suitable sample, and unsuitable samples.

**N.B.:** Do not use any active heating mechanism such as warm water or a hair dryer to warm baby’s heel prior to undertaking newborn bloodspot screening as there is a risk of thermal burns from such practice.
8.4 Sample collection from central line in sick babies

On occasion the blood sample may be collected from a central line. Ensure that sufficient blood is discarded prior to placing drops of blood on the card. Failure to do this may result in a dilute sample and give false negative results.

8.5 Packing and dispatching the newborn bloodspot screening cards

a) Send the NBS card by registered post or by courier to the NNBSL using the yellow fluorescent address labels, to reach the laboratory as soon as possible after collection. Do NOT store or batch the completed NBS cards.
b) If more than one NBS card is placed in an envelope, they should be placed at 180° to each other so that blood does not touch blood.
c) The sender MUST indicate how many NBS cards have been placed in each envelope and provide a separate list of the names of the babies and UPIs whose specimens have been included in each envelope.
d) Keep a record of all samples sent in each envelope; a sample checklist is available for downloading from the newbornscreening.ie website.
e) Dispose of lancets as per local guidelines; never enclose the lancet in the envelope with the NBS card. Please read Section. 9 on the transport of samples.
### 8.6 Quality of the bloodspot sample

Please ensure that there is an adequate amount of blood on the NBS CARD that completely fills each circle. An inadequate amount of blood or a poor quality dried bloodspot will require the procedure to be repeated causing potential trauma to the baby, anxiety to the parent(s)/legal guardian(s) and inconvenience to the sample taker and may result in delay in making a diagnosis.

**Figure 4: Quality of suitable and unsuitable dried bloodspots**

<table>
<thead>
<tr>
<th>Quality of Dried Bloodspot</th>
<th>Possible Causes/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="Insufficient sample" /></td>
<td>Insufficient blood collected</td>
</tr>
<tr>
<td></td>
<td>Blood should be soaked through from back to front to provide sufficient sample for analysis</td>
</tr>
<tr>
<td><img src="image" alt="Sample received wet" /></td>
<td>Sample sent to laboratory before completely dry</td>
</tr>
<tr>
<td></td>
<td>Wet samples can give a false result and pose a health and safety risk to staff</td>
</tr>
<tr>
<td><img src="image" alt="Sample over saturated/layered" /></td>
<td>Applying layers of blood to card</td>
</tr>
<tr>
<td></td>
<td>Applying blood to both sides of card</td>
</tr>
<tr>
<td><img src="image" alt="Sample appears contaminated" /></td>
<td>Squeezing area surrounding puncture site</td>
</tr>
<tr>
<td></td>
<td>Allowing card to come in contact with gloved hands or substances such as milk, hand lotion etc.</td>
</tr>
<tr>
<td></td>
<td>Blood spot sample being compressed, causing cells to separate resulting in a diluted sample in the centre of spot</td>
</tr>
<tr>
<td><img src="image" alt="Sample shows serum rings" /></td>
<td>Allowing card to come in contact with liquids e.g. hand lotion, water, milk.</td>
</tr>
<tr>
<td></td>
<td>Drying specimen incorrectly, or dispatching to laboratory when still wet</td>
</tr>
<tr>
<td><img src="image" alt="Good quality blood sample with enough blood should a test need to be repeated" /></td>
<td>Sufficient amount of blood to soak through to completely fill all circles</td>
</tr>
<tr>
<td></td>
<td>N.B.: 3.2 mm punches are taken from the card, all testing calculations are based on a completely filled punch, this is why a fully saturated spot is essential</td>
</tr>
</tbody>
</table>
8.7 Why repeat blood samples may be requested

1. Insufficient blood on card for all or some of the screens to be performed.
2. Unsatisfactory sample quality – compressed/diluted sample, serum rings or contaminated.
3. Abnormal, borderline or equivocal test result.
4. Baby too young when blood sample was collected, sample collected before 72 hrs. after birth.
5. Blood on the card not dried properly before being put into a plastic coated Tyvek® envelope, thus causing serum rings or a diluted sample.
6. There is a query about the identification of the baby or babies if multiple births.
7. The sample was taken on an expired card.
8. The card was delayed, greater than 14 days getting to the NNBSL and is too old for analysis which can result in a false negative.
9. The bloodspot portion of the NBS card and demographic portion were re-attached but NBS card barcodes do not match up.
10. The name on the bloodspot portion does not match that on the demographic portion of the card; the identity of the baby may need clarification or a repeat sample.
11. Sample is unsuitable for analysis if taken within 72hrs of a RBC transfusion.

N.B. It is the responsibility of the sample taker to tell the parents the correct reason why the repeat sample is required.

8.8 Problems with card demographics incorrectly completed

Unlabelled or inadequately labelled specimens cannot be accepted for analysis.

8.9 Bio-hazard samples

Newborns, whose mothers are known or suspected of being infected with an infectious disease e.g. Covid19, HIV or Hepatitis B, MUST have the screen performed in the 72-120 hr. window.

The word ‘Biohazard’ to be noted on the card, but nature of biohazard should not be noted as it is not relevant to screens being performed.

The sample should be placed in a biohazard bag (or ‘Biohazard’ noted on bag/envelope) once completely air dry. The outer envelope does not require the UN3373 sticker, and ‘Biohazard’ does not need to be noted on the outer envelope.

All samples received ‘wet’ pose a health and safety risk to staff and may give a false result, due to possible sample contamination or separation, please allow cards to fully air-dry.

8.10 Completion of newborn bloodspot screening card at time of discharge

It is the practice of some maternity units/hospitals to give the NBS card to the parent(s)/legal guardian(s) either completed or blank at the time of discharge from hospital. It is the responsibility of the sample taker to check that ALL the details are
correct, including the date and time of collection. In addition, the name of the baby, both surname and first name may have changed since discharge and these corrections MUST also be made. The responsibility for above lies with sample taker.

9 Transport / drying boxes and pre-printed plastic envelopes

The NNBSL has designed drying/transport boxes in conjunction with Mega-Pak Ltd, to facilitate the transport of samples from the baby’s home to the PHN’s car in a safe manner. Once the bloodspot has dried, the sample should be removed from the box and packaged according to the regulations. These boxes can contain two cards and are reusable. However, if they become contaminated with blood they should be disposed of either by incineration or through the accepted procedure for disposal of hazardous waste. These boxes can be ordered directly from Mega-Pak Ltd – the minimum order is 150 boxes, flat packed in batches of 50.

Mega-Pak Ltd (Irish Office)
16 Highfield Green
Swords, Co. Dublin

Tel: +353 (0) 1 840 2063
Fax: +353 (0) 1 840 2063
e-mail: megapakireland@eircom.net
Website: www.mega-pak.com

Figure(s) 5: Transport/Drying Box

9.1 Procedure for transporting samples

The sender of samples by registered post or by courier is responsible for ensuring that the packaging and transportation of the sample complies with current transport regulations regarding Health and Safety as laid down in the European Directive (ADR 2015) Packaging Regulations P650. Dried bloodspots must be packaged appropriately. NNBSL
recommends that once the blood has dried, the sample should be inserted into a water resistant, tear proof Tyvek® envelope or equivalent. The yellow fluorescent address label should be fixed to the outer envelope.

**Pre-printed registered envelopes**
Pre-printed plastic envelopes may be purchased directly from An Post by e-mailing customer care at An Post.

Please send an email for the envelopes to customer care, stating the amount of envelopes required and quoting a HSE purchase order number.
A Pro Forma invoice, with the HSE purchase order number as reference, will then be returned to enable payment by EFT. Once the EFT payment has reached An Post’s bank account the Philatelic Section will despatch the order.

### 9.2 Responsibility of sender

If more than one screening card is put in an envelope, they should be placed at 180° to each other (i.e. the bloodspots should not overlap and therefore not touch). The sender should state in writing how many cards are in each envelope and include a list of the names of the babies; a sample checklist is available to download from [www.newbornscreening.ie](http://www.newbornscreening.ie) (see appendix 9).

Screening cards, appropriately packaged, should be sent daily and not batched. It is the responsibility of the sender to dispatch the sample as soon as possible after collection, either by registered post or by courier. It is not appropriate to put the package into the post knowing that there may be a delay in it arriving at the NNBSL due to either a postal dispute (local or national) or over the Christmas period when the post is delayed. Alternative arrangements should be made by maternity units/hospitals and CHO/LHOs to ensure samples are despatched to NNBSL without delay. Parents should never be asked to post or deliver samples to the NNBSL. This is the responsibility of the sample taker.

**Important information for samples due to be taken on Thursdays (all year round)**
To ensure samples reach our laboratory in a timely manner and to minimise a delay in reporting, can we ask that samples due to be taken on a Thursday, are collected early Thursday morning if **baby is 72 hours old**, allow sample to dry fully, and **post on Thursday afternoon** to arrive in our laboratory on Friday morning for analysis.

### 9.3 Red weather alerts

In the event of a red weather alert due to adverse weather conditions, the sample taker in conjunction with the ADOM / ADPHN must assess the risk of travel of either the PHN or the parent and baby against the risk of delayed screening. Further advice can be sought from the laboratory on such occasions.
10 Procedure for reporting results

Parent(s)/legal guardian(s) are entitled to and can be given a copy of baby’s results by their PHN.

All Newborn Screening reports are transmitted electronically via eReporting™ to
- The maternity unit/hospital of birth
- To the baby’s LHO
- And to the referral or tertiary hospital if baby has been transferred and this is noted on the card

Therefore, it is essential that the correct LHO is recorded on the sample, and the parent(s)/legal guardian(s) residence Eircode.

eReporting™ is a secure data protected means of transmitting newborn screening reports. No paper copies of reports are now issued by the NNBSL. eReporting is password protected, only those with access to eReports can view results. It allows designated staff in the respective maternity unit/hospital and LHOs to review the reports in pdf format. The reports are available to view for 60 days from the date of issuing. They are then archived in the NNBSL.

10.1 Setting up authorised users for eReports
Each maternity unit/hospital and LHO nominates two authorised users; each will require access to the internet. Staff from the NNBSL will provide them with a User Name and User ID. They will also be provided with the internet link in order to access eReports.

Use of eReporting
- Authorised users can verify that a NBS sample has been received by the NNBSL.
- Results are available as soon as they have been authorised by laboratory staff, usually within 2 days of receipt of the sample.
- As requests for repeat samples are sent electronically, these repeat samples can be taken sooner.
- A search facility can be used to find or link results; this includes baby’s or mother’s surname, baby’s UPI and DOB or range of dates within the previous 60 days.
- Individual baby newborn bloodspot reports can be printed locally and then filed in the healthcare record and/or a copy given to the parent(s)/legal guardian(s).

10.2 Requests for repeat sampling and responsibility for checking eReports
Authorised users must review eReports daily and notify colleagues if a repeat sample has been requested. The reason for requesting a repeat sample will be indicated on the individual report.
If results are sent to a LHO that a baby does not reside in, an 'incorrect location form' can be completed and the location changed; forms are available on the website or see appendix 1. The report will then be resent to the correct LHO.
11 Procedure for contacting parent(s)/legal guardian(s) with a screen positive result

Parent(s)/legal guardian(s) of a baby with a suspected positive screen are contacted directly by telephone by the maternity unit/hospital. The procedure varies slightly depending on the condition suspected. The NNBSP Governance Group has set out Key Performance Indicators to ensure that babies detected with a condition are diagnosed and established on treatment within a specific time interval. The general procedure for contacting parent(s)/legal guardian(s) is set out below with more specific details depending on the condition.

Procedure of contacting parent(s)/legal guardian(s) with screen positive results

- The Clinical Liaison Officer (or, depending on the condition the Director) in the NNBSL contacts a designated liaison nurse or paediatric registrar in the maternity unit/hospital by telephone – the following information is given:
  - The baby’s name, UPI, DOB and address
  - The disorder suspected and the result of the screening test
  - The designated liaison nurse or registrar in the maternity unit/hospital will be asked to locate the baby and parent(s)/legal guardian(s) and explain to them;
    - Why the baby has to be referred to hospital.
    - What disorder is suspected.
    - Why a further card or blood sample is required, or thyroid scan if CHT suspected.
- Arrange for the baby to be brought directly to CHI at Temple Street, CHI at Crumlin or to the local Paediatric Unit as requested by the NNBSL or the CHI at Crumlin Immunology team (in the case of ADA-SCID).
- Parent(s)/legal guardian(s) should be advised that their baby might be kept in hospital for a few days, depending on the result of the repeat investigation. Therefore, they should bring change of clothes for the baby and themselves.
- The designated liaison nurse or registrar may contact the Director of the NNBSL or deputy through the CHI at Temple St switch board if further information is required.

At all times the designated liaison nurse or registrar must not instil any degree of anxiety when communicating with the parent(s)/legal guardian(s) but must impart the information in a calm and professional manner, being fully informed of all the facts.

11.1 Follow up for suspected positive cases of PKU

The Clinical Liaison Officer in the NNBSL will book a bed for admission to CHI at Temple Street and liaise with the on-call metabolic team. The designated liaison nurse in the maternity unit/hospital will be contacted and asked to:
• Arrange for the baby to attend CHI at Temple Street Hospital under the care of the on-call Metabolic Paediatrician;
• Give the contact number of the NNBSL to the parent(s)/legal guardian(s), and invite them to make contact for more information, if they wish to do so.

Babies with PKU are given a trial of the drug Kuvan, to test for responsiveness. This requires admission to Temple St, ideally before day 10 of life. During this time the baby will also be started on lifelong dietary treatment and the parents will receive instruction on the monitoring and dietary management of their baby.
Babies with a milder variant of the condition may be referred to the outpatient clinic. This information will be clearly given to the designated liaison nurse at the time of the initial contact.

11.2 Follow up for suspected positive cases of MSUD

The Director of the NNBSL or deputy will discuss the case with the on-call Metabolic Paediatrician. He/She will then either contact the designated liaison nurse or the Paediatric Registrar in the maternity unit/hospital directly and arrange for the baby to be admitted as a matter of urgency, either to the local Special Care Baby Unit or directly to CHI at Temple Street.

If the baby is to be admitted to:
• the local SCBU team;
  – Explain to the parents what disorder the baby is suspected of having
  – On admission, examine the baby in detail and check the urine/blood for the presence of ketones;
  – Arrange for 2mL of whole blood collected into a lithium heparin tube for plasma branch chain amino acids to be sent immediately to the Metabolic Laboratory, Temple Street.

Contact the on-call Metabolic Paediatrician at Temple Street for further advice on management.
• CHI at Temple Street;
  – Parent(s)/legal guardian(s) must be informed that the baby will be admitted to hospital until the results of tests are known. If the diagnosis is confirmed, the baby will remain in hospital until the Metabolic Paediatricians are satisfied that the baby’s condition is under control and that the parents will be able to cope at home.
11.3 **Follow up for suspected positive cases of HCU**

The Director, Clinical Liaison officer or deputy will contact the designated liaison nurse. The designated liaison nurse will be asked to:

- Locate the baby and parent(s)/legal guardian(s) and explain to them why a blood sample is required and what disorder the baby is suspected of having;
- Arrange for the baby to have a blood sample taken 2 mL of whole blood collected into a lithium heparin tube for methionine, total homocysteine and liver functions tests.

If the plasma methionine and total homocysteine are raised this supports the diagnosis, arrangements will be made for the parent(s)/legal guardian(s) to attend the Metabolic outpatient at CHI at Temple Street.

11.4 **Follow up for suspected positive cases of Classical Galactosaemia**

The Director, Clinical Liaison officer or deputy will contact the Paediatric Registrar in the maternity unit/hospital to arrange immediate admission to the local Paediatric unit. They will be asked to:

- Locate the baby and parent(s)/legal guardian(s) as a matter of urgency;
- Explain the nature of the condition and to bring their baby directly into the local paediatric unit where the baby will be admitted to hospital for further investigations.

On admission, all lactose and galactose containing feeds including breast milk should be replaced by soya-based feeds. The baby should be examined and the following investigations performed:

- Liver function tests
- Coagulation screen
- Blood cultures (to exclude, for example, *E coli* septicaemia)
- Repeat screening card

As soon as the results of the investigations are available the local clinicians must contact the on-call Metabolic Paediatrician at Temple Street Children’s University Hospital to discuss further action.
11.5 Follow up for suspected positive cases of MCADD

The Director, Clinical Liaison officer or deputy will contact the Paediatric Registrar in the maternity unit/hospital. They will be asked to:

- Locate the baby and parent(s)/legal guardian(s) as a matter of urgency;
- Explain the nature of the condition suspected and to bring their baby directly into the local paediatric unit for assessment and further investigations.

All babies with an MCADD suspected screening result should be referred to the Metabolic Unit Temple St. on the same day the screening result is available. The following tests should be performed: urine organic acids and DBS acylcarnitines and the following may be considered: blood glucose, liver function tests, ammonia and CK.

N.B.: Feeds protocol for MCADD screen positives or babies at high risk

It is essential to ensure that the baby maintains a good milk intake until results are available. If baby is well it should be bottle fed every 3 hours or if breast fed every 2-3 hours during day time and every 3 hours at night (at least 10 minutes on the breast). Exclusively breast fed babies are particularly at risk in the first few days when the supply of breast milk is poor; top up feeds of expressed breast or formula milk may be necessary until a good milk supply is established. Seek advice from the Metabolic clinical team in Temple St.

If oral feeds are not tolerated, or if the baby is unwell in any way, urgent referral should be made to a Metabolic Paediatrician for review and consideration of IV glucose.

11.6 Follow up for suspected positive cases of GA1

The Director, Clinical Liaison officer or deputy will contact the Paediatric Registrar in the maternity unit/hospital. They will be asked to:

- Locate the baby and parent(s)/legal guardian(s)
- Explain the nature of the condition suspected and to bring their baby directly into the local paediatric unit or Temple St. for assessment. If advised by Metabolic Consultant the baby may be admitted to hospital following further investigations.

All babies with a GA1 suspected screening result should be referred to the Metabolic unit Temple St. on the same day the screening result is available. The following tests should be performed: urine organic acids and DBS Acylcarnitine profile, Renal profile (locally). A liver profile may be considered (locally).

N.B.: Feeds protocol for GA1 screen positives

Feeding routine needs to be established and the baby must continue with regular feeding. If oral feeds are not tolerated, or if the baby is unwell in any way, urgent referral should be made to a Metabolic Paediatrician for review and consideration of IV glucose.
11.7 Follow up for suspected positive cases of Cystic Fibrosis

The results of the screening test will be available by approximately the third week of life:

- The Clinical Liaison Officer will contact the designated liaison nurse in the maternity unit/hospital to obtain the parent(s)/legal Guardian(s) contact details and any relevant clinical information. She/he will then contact the CF Nurse Specialists in the appropriate HSE designated paediatric CF Centres, to give them the full contact details, relevant clinical information and the results of the mutational screen.
- The CF nurse specialist will book a sweat test appointment, and then contact the parent(s)/legal guardian(s) to arrange for the baby to attend the nearest CF centre the following day.

On arrival, the parents will be fully informed as to what will happen; the baby will have a sweat test, the results of which should be available by early afternoon on the same day if sufficient sweat is collected. Depending on the results of the sweat test, the parents will be informed that their baby has CF or is a carrier of the condition. If the baby is considered to be a CF carrier and is therefore unlikely to have CF the parents will be referred for genetic counselling.

HSE Designated Paediatric CF Centres

- Dublin: CHI at Temple St.
  - CHI at Crumlin
  - CHI at Tallaght
- Cork: Cork University Hospital
- Limerick: University Hospital Limerick
- Galway: University College Hospital, Galway

11.8 Follow up for suspected positive cases of Congenital Hypothyroidism

The procedure may vary slightly depending on the age of the baby, the degree of elevation of the blood Thyroid Stimulating Hormone (TSH) level and referral hospital. However, clear instructions will be given. The designated liaison nurse will be asked to:

- Locate the baby and parent(s)/legal guardian(s)
- Explain to the parent(s)/legal guardian(s) what disorder is suspected
- Arrange for the baby to attend the designated hospital to be examined, have blood tests performed, and a thyroid scan; depending on thyroid function test result, following which the baby will usually be started on thyroid hormone replacement.

If the blood TSH level is confirmed as being very high, and if the baby is approaching ten days of age, thyroid hormone replacement may be started before they attend the hospital for a thyroid scan.
The NNBSL on occasion performs TSH analysis on dried blood spot samples from Down Syndrome patients, as it is often less traumatic than a venous sample.

11.9 Follow up for suspected positive cases of ADA-SCID

The Director, Clinical Liaison officer or deputy will contact the Paediatric Registrar in the maternity unit/hospital. They will be asked to:

- Locate the baby and parent(s)/legal guardian(s) as a matter of urgency;
- Explain the nature of the condition suspected and to bring their baby directly into the local paediatric unit for assessment and further investigations.

Upon attendance take 2mls of EDTA (fresh, whole blood, ambient temperature, do not freeze) and send immediately to the Immunology laboratory in St. James’s Hospital for flow cytometry and ADA enzyme analysis. Perform a clinical evaluation of the baby this must be discussed with CHI at Crumlin Immunology team to determine whether the infant needs hospital admission or can be discharged home to await blood results. NNBSL will give specific instructions on the above requirements at the time of a screen positive.

Acknowledgements

We would like to acknowledge the dedication and commitment that so many different healthcare professionals put into this programme for the benefit of the few babies born each year who are affected by one of these conditions.

We would welcome any comments and feedback that individuals may have on this edition. More information about the programme may be obtained at: www.newbornscreening.ie and www.hse.ie/go/newbornscreening.

12 Appendices

Appendix No. 1: Incorrect Location Form
Appendix No. 2: Opt-Out Form
Appendix No. 3: Scan of Newborn Bloodspot Screening Card
Appendix No. 4: Copy Result Request Form
Appendix No. 5: eReporting User Information
Appendix No. 6: Patient Detail Amendment form
Appendix No. 7: Metabolic Follow-up sample request form
Appendix No. 8: ADA SCID Follow-up sample request form
Appendix No. 9: Sample Checklist
Appendix No. 1    Incorrect Location Form

National Newborn Bloodspot Screening Laboratory
A INAB accredited testing Laboratory Reg.No.224MT
Temple Street Children's University Hospital, Dublin 1
Direct Line: Ph (01) 8784277 Fax (01) 8784698 www.newbornscreening.ie Email: info.newbornscreening@cuh.ie

Please complete details below on babies on whom you have received reports which do not belong to your
Area and return to NNBSL. Please indicate correct LHO (only if known).

Please FAX or email to NNBSL as soon as possible.

<table>
<thead>
<tr>
<th>Location (LHO):</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported By:</td>
<td>Position:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>UPI</th>
<th>Lab Number</th>
<th>Date of Birth</th>
<th>Correct LHO (if known)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comment:

Page 1 of 1

Author: Karen Hunter
Ref: LP-NNS-0001
Date of issue: 06/07/2016
Authoriser: Loretta O’Grady
Appendix No. 2  Opt Out Form

NATIONAL NEWBORN BLOODSPOT SCREENING PROGRAMME

OPT-OUT FORM

<table>
<thead>
<tr>
<th>Baby's Unique Perinatal Identifier (UPI):</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Baby's Surname:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baby's First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baby's Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mother's Surname:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time of Birth:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Birth Weight (g):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Birth:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RBC Transfusion Received?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of First Transfusion:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time of First Transfusion:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of First Feed:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Local Health Office:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- * I am the parent/guardian of Baby
- * I do not consent to allow the Newborn Bloodspot Screening Test (Heel-Prick) to be carried out on my baby.
- * I have read the information leaflet on Newborn Bloodspot Screening and the test has also been explained to me.
- * I fully understand the importance of the decision that I am taking by not allowing my baby to be tested.
- * I understand that not detecting or treating one of the conditions, should baby have one, may result in severe intellectual or physical disability which could require long term care or result in premature death.

Signed (Parent/Guardian): ___________________________ Date: ____________________
Full Name (PRINT): ___________________________ Date: ____________________
Signed by potential sample taker: ___________________________ Date: ____________________
Position/Job Title: ___________________________ Health Area Office: ___________________________

OFFICIAL USE ONLY

6 copies of the completed form, signed by parent/guardian and sample taker should be made. A copy to be given to the parent/guardian and a copy kept by the sample taker.

Copies are to be posted to each of the following: The Director of Nursing/Midwifery * Director of Public Health Nursing * National Newborn Bloodspot Screening Laboratory * The baby’s General Practitioner

<table>
<thead>
<tr>
<th>Director of Nursing/Midwifery</th>
<th>Director of Public Health Nursing</th>
<th>National Newborn Bloodspot Screening Laboratory (NNBLSL)</th>
<th>General Practitioner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address</td>
<td></td>
<td>NNBLSL, Children’s University Hospital, Temple Street, Dublin 1</td>
<td></td>
</tr>
<tr>
<td>Date Sent</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Signed (Sample taker): ___________________________ Date: ____________________
Name (Block Capitals): ___________________________

N.B.: The cystic fibrosis screen is not suitable if baby is over six weeks of age.

Parents/Guardians may change their mind but it is their responsibility to inform the GP or Public Health Nurse.
Appendix No. 3  
Scan of Newborn Screening card (front and back)
Appendix No. 4  Copy result request form

Available from laboratory, email info.newbornscreening@cuh.ie
Appendix No. 5  Specimen Gate eReports™ instructions

To access e-reports: In your internet browser type or copy the following URL and save to favourites. http://sgateweblive.healthirl.net/ereports or http://10.0.37.81/ereports

Each user, logins using their own ‘user name’ and ‘password’ assigned by the NNBSL, see below

From here it is possible to search for a specific sample or download list or single reports.

Welcome to eReports
You have 0 unread messages.

Specimen Search

<table>
<thead>
<tr>
<th>Enter name</th>
<th>Mother’s surname</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOB from (DD/MM/YYYY)</td>
<td>DOB to (DD/MM/YYYY)</td>
</tr>
<tr>
<td>URI</td>
<td>Date of collection (DD/MM/YYYY)</td>
</tr>
</tbody>
</table>

Search  Clear

Download Reports

<table>
<thead>
<tr>
<th>Employee</th>
<th>Reports</th>
</tr>
</thead>
</table>

Show All Reports

To Download Reports

- Select ‘Download Reports’ (left hand side menu) – the most recent reports (list and single) for your location will be visible to each user in pdf format.
- In this view, select ‘List Report’ to open the latest List Report of normal results or select ‘Single Report’ to open separately in pdf viewer.
- Select ‘Show all Reports’ to view / print all reports for the previous 60 days.

Note: If reports have been archived after 60 days they will need to be individually regenerated. If reports are greater than 18 months they cannot be regenerated.
To do a search for a Specific Sample or group of samples select ‘Specimen Search’ (left hand menu). Use below criteria, use DOB either for 1 day or a range.

**A specific sample can be searched for**

**Example:** To search for a Baby Murphy DOB 11/03/2013 (MUST be dd/mm/yyyy)

Select ‘search’ for the following screen:

**Report:** To view the report select ‘View Report List’ from left hand side ‘Report’ column to open. If the sample has been received in the laboratory but the results are not yet available then this will be viewed as ‘Results Pending’.

**Determination:** The ‘Determination’ column will display ‘Normal’ if all the requested tests have a result of ‘Not Suspected’. This column will display ‘other’ if a result for any condition is abnormal and/or a repeat card is required.

**Note:**
1. To search for all samples from your location for a particular DOB enter range only: all babies with DOB of 14/05/2013 enter from 14/05/2013 to 14/05/2013.
2. To search by UPI, dash (-) must be placed after the three digit HIPE Code and ensure that the letter (if any) is included e.g. Coombe 930-B12345678.
Appendix No. 6  Patient Detail Amendment form
Available from laboratory, email info.newbornscreening@cuh.ie

This form is to gather only required information to complete babies' newborn bloodspot screen and to comply with GDPR regulations. Amend incorrect details that were recorded by sample taker or in the laboratory and comply with GDPR regulations.

Re: Lab sample no. XX-XXXXX

Baby's surname:

DOB:

Baby's Unique Perinatal Identifier:

Address:

Hospital of birth:

Dear NNBSL please amend the following details on baby noted above:

Signed by:

Position:

PRINT NAME:

Phone no:

Please forward to:
- Secure email info.newbornscreening@cuh.ie

NOTE: If attaching additional documentation please ensure it only contains required information on baby, not mother in order to comply with GDPR regulations, e.g. birth notification not suitable as mums history attached and not appropriate to share outside Maternity unit.
All documents received will be attached to patient record and stored permanently.

Lab use only

Source of error: Lab/UHO/Maternity unit /Other (please circle)
Details checked on UMS: Disclaimer added:
Sample quality checked: Results reviewed:
Amended by: PC action complete:
Sign:

Author: Catherine Harvey Ref: LP-NNS-0047 & 0057 Date of issue: 19/04/2022
Authoriser: Loretta O’Grady
Appendix No. 7  Metabolic follow-up sample request form
Available from laboratory, email info.newbornscreening@cuh.ie
### Appendix No. 8  ADA SCID follow up sample request form

Available from laboratory, email info.newbornscreening@cuh.ie

---

**National Newborn Bloodspot Screening (NNBS) CHI Temple St, DPLM**

**ADA SCID Newborn Screening Follow-Up Request Form**

<table>
<thead>
<tr>
<th>Sample Taken Please Complete</th>
<th>Suspected Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternity/Paediatric Hospital</td>
<td>ADA SCID on Newborn Screen</td>
</tr>
<tr>
<td>Baby Hospital No / MRN</td>
<td></td>
</tr>
<tr>
<td>Surname</td>
<td></td>
</tr>
<tr>
<td>First Name</td>
<td></td>
</tr>
<tr>
<td>Date of Birth (DD-MM-YYYY)</td>
<td></td>
</tr>
<tr>
<td>Gender M/F</td>
<td></td>
</tr>
<tr>
<td>Date &amp; Time of Test</td>
<td></td>
</tr>
<tr>
<td>Referring Paediatrician (Print Name)</td>
<td></td>
</tr>
<tr>
<td>Contact Number</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Sample Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 ml of EDTA (fresh whole blood ambient temperature)</td>
<td>Send immediately (taxi) to Immunology Dept, St James’ Hospital, Dublin D08 NY1</td>
</tr>
</tbody>
</table>

**Investigation Required**

- ADA SCID (TBK1, Naive and Activated T cells ADA Enzyme and Metabolite Screen)

**Address for Reporting**

NNBS, CHI Temple St, Department of Paediatric Laboratory Medicine  email info.newbornscreening@cuh.ie  contact no 01 8784277

Immunology Department, CHI Crumlin  email Immunology@chc.ie  contact no 01 409 8883

**Receipt of Sample in St James**

<table>
<thead>
<tr>
<th>Date and Time Received</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date sufficient for Flow Testing (Y/N)</td>
<td></td>
</tr>
<tr>
<td>Date sufficient for ADA Enzyme and Metabolite Screen (Y/N)</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE TO REFERRING LABORATORY:** Please use this request form ONLY for Newborn ADA-SCID Screening Follow-up.
Appendix No. 9  Sample Checklist

Temple Street Children's University Hospital, Department of Paediatric Laboratory Medicine
LF-NNS-0111  NNS Screening Card Checklist  EDITION 1

**IMPORTANT** — Ensure samples are dry, envelopes are sealed and no lancets enclosed

Please complete this form and list each baby's name and UPI as written on the screening cards. This form should be included in all envelopes containing more than one screening card.

The National Newborn Bloodspot Screening Laboratory,
Children’s University Hospital, Temple Street, Dublin 1, D01 YC67
Ph: 01 8784610/4277

<table>
<thead>
<tr>
<th>Location:</th>
<th>Contact No.:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of cards:</td>
<td>Date Posted:</td>
</tr>
<tr>
<td>Checked by:</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Baby’s Surname (as on card)</th>
<th>Baby’s UPI (as on card)</th>
<th>Additional Comment if relevant</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For office use only — checked by: ___________________________  Website: www.nmap.ie

Author: Karen Hunter  Ref: LP-NNS-0001  Date of issue: 06/07/2016
Authoriser: Loretta O’Grady